



Disponible en ligne sur

ScienceDirect  
www.sciencedirect.com

Elsevier Masson France

EM|consulte  
www.em-consulte.com



## Guidelines

# Cardiac rehabilitation recommendations of the Group Exercise Rehabilitation Sports – Prevention (GERS-P) of the French Society of Cardiology: 2023 update

Muriel Bigot<sup>a,\*</sup>, Jean Michel Guy<sup>b,1</sup>, Catherine Monpere<sup>c</sup>, Alain Cohen-Solal<sup>d</sup>, Bruno Pavy<sup>e</sup>, Marie Christine Iliou<sup>f</sup>, Gilles Bossier<sup>g</sup>, Sonia Corone<sup>h</sup>, Herve Douard<sup>i</sup>, Titi Farrokhi<sup>h</sup>, Antoine Guerder<sup>j</sup>, Pascal Guillo<sup>k</sup>, Jean-Pierre Houppé<sup>l</sup>, Theo Pezel<sup>m</sup>, Bernard Pierre<sup>n</sup>, Stephane Roueff<sup>o</sup>, Daniel Thomas<sup>p</sup>, Benedicte Verges<sup>q</sup>, Jean Christophe Blanchard<sup>r</sup>, Mohamed Ghannem<sup>s,t</sup>, Dany Marcadet<sup>u</sup>

<sup>a</sup> Centre de réadaptation cardiaque, Cardiocéan, 17138 Puilboreau, France

<sup>b</sup> Le Clos Champirol rééducation, 42270 Saint-Priest-en-Jarez, France

<sup>c</sup> SMR Dieulefit Santé, 26220 Dieulefit, France

<sup>d</sup> Service de cardiologie, centre de réadaptation cardiaque, hôpital Lariboisière, Assistance publique–Hôpitaux de Paris, Inserm UMRS-942, université Paris Cité, 75010 Paris, France

<sup>e</sup> Service de réadaptation cardiovasculaire, CH Loire Vendée Océan, 44270 Machecoul, France

<sup>f</sup> Centre de réadaptation cardiaque, groupe hospitalier Paris Saint-Joseph, 75014 Paris, France

<sup>g</sup> Service de cardiologie pédiatrique et congénitale, CHU Nancy, 54600 Vandœuvre-Lès-Nancy, France

<sup>h</sup> Service réadaptation cardiaque, centre hospitalier de Bligny, 91640 Briis-sous-Forges, France

<sup>i</sup> CHU Bordeaux, Pessac, France

<sup>j</sup> Service de pneumologie, hôpital Pitié-Salpêtrière, Assistance publique–Hôpitaux de Paris, 75013 Paris, France

<sup>k</sup> Centre de réadaptation Saint-Yves, 35000 Rennes, France

<sup>l</sup> Cardiologie, 04870 Saint-Michel L'Observatoire, France

<sup>m</sup> Service de cardiologie, hôpital Lariboisière, AP–HP, université Paris Est Créteil, 75010 Paris, France

<sup>n</sup> Faculté de médecine, Lyon Sud, 69310 Lyon, France

<sup>o</sup> Service de néphrologie, hôpital européen Georges-Pompidou, Assistance publique–Hôpitaux de Paris, 75015 Paris, France

<sup>p</sup> Institut de cardiologie Pitié-Salpêtrière, AP–HP, 75013 Paris, France

<sup>q</sup> 21000 Dijon, France

<sup>r</sup> 25200 Montbéliard, France

<sup>s</sup> Service de cardiologie, hôpital de Gonesse, faculté de médecine, Sousse, Tunisia

<sup>t</sup> Université Picardie Jules-Verne, 80000 Amiens, France

<sup>u</sup> 75008 Paris, France

## ARTICLE INFO

### Article history:

Received 4 February 2024

Received in revised form 15 May 2024

Accepted 16 May 2024

Available online xxx

## ARTICLE INFO

### Keywords:

Cardiac rehabilitation

Exercise training

Secondary prevention

Group Exercise Rehabilitation Sports – Prevention (GERS-P)

## 1. Abbreviations

1-RM	one-repetition maximum
ACS	acute coronary syndromes
COPD	chronic obstructive pulmonary disease
CPAP	continuous positive airway pressure
CPET	cardiopulmonary exercise test
ECG	electrocardiogram

\* Corresponding author.

E-mail address: [mubig.mb@gmail.com](mailto:mubig.mb@gmail.com) (M. Bigot).

<sup>1</sup> †.

<https://doi.org/10.1016/j.acvd.2024.05.119>

1875-2136/© 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Please cite this article as: M. Bigot, J.M. Guy, C. Monpere et al., Cardiac rehabilitation recommendations of the Group Exercise Rehabilitation Sports – Prevention (GERS-P) of the French Society of Cardiology: 2023 update, Arch Cardiovasc Dis, <https://doi.org/10.1016/j.acvd.2024.05.119>

ESC	European Society of Cardiology
FITT	frequency, intensity, time and type
GERS-P	Group Exercise Rehabilitation Sports – Prevention
HAS	Haute Autorité de santé (French National Authority for Health)
HbA1c	glycated haemoglobin
HF	heart failure
HR	heart rate
ICD	implantable cardioverter-defibrillator
INR	international normalized ratio
MDMA	methylenedioxy-methylamphetamine (ecstasy)
MET	metabolic equivalent of task
OSAS	obstructive sleep apnoea syndrome
QoL	quality of life
TAVI	transcatheter aortic valve implantation
VKA	vitamin K antagonist
VT1	first ventilatory threshold
VT2	second ventilatory threshold

## 2. Background

Cardiac rehabilitation is a therapy in its own right, on the same level as pharmacological, interventional and surgical treatments. Combining exercise training, patient education and optimization of treatments, it is a unique holistic and multidisciplinary patient management approach, which should be proposed for patients with cardiovascular disease. Despite excellent proven benefits in terms of morbidity and mortality, quality of life (QoL) and exercise capacity, it remains insufficiently prescribed and accessible. Nevertheless, numerous publications have validated its safety and efficiency. In addition, it is classed as a rank I A therapy according to European guidelines on cardiovascular disease prevention [1] and for ischaemic cardiac disease [2] or for heart failure [3].

This update of the 2012 French recommendations [4] presents new indications, more modern methods for exercise training and how they should be prescribed, reviews the new regulatory aspects of medical care and rehabilitation, and provides new options in order to propose programmes that are better adapted to patient profiles, more diversified and more readily accessible.

Even though some questions remain unanswered and some subjects still debated, the relevance of cardiac rehabilitation has never been so clearly validated and recognized. The foreseeable changes in terms of risks and cardiovascular disease in the population further reinforce its indispensable nature. In this article, we will also address the perspectives and some improvements to be made to ensure a larger number of patients can benefit from better-adapted programmes, more flexible patient management duration and more varied modalities. Based on these adaptations, it should be possible to achieve the public health objective of reducing cardiovascular risks and optimizing holistic patient management.

## 3. Indications for cardiac rehabilitation

The assessment of the indications considers the level of proof (class I to III) and the degree of evidence (grade A to C) as determined in the European recommendations [1]. In all cases, this is based on exercise training associated with [5]:

- the cardiovascular risk factors should be verified and updated as necessary;
- educational aspects (nutrition, tobacco, stress, etc.) and psychological care are essential;
- cardiac rehabilitation must also allow treatment optimization [6];
- return to work should remain a priority for patients still active in the workforce.

In specific cases, cardiac rehabilitation should allow:

- management of nursing care (scar care, etc.) as well as specific and accentuated monitoring;
- management of vitamin K antagonists (VKAs), prevention of the risk of endocarditis, management of immunosuppressive treatment, management of an implantable cardioverter-defibrillator (ICD), etc.

### 3.1. Coronary heart disease (non-surgical)

Cardiac rehabilitation in patients with coronary heart disease reduces cardiac mortality by 26%, rehospitalization by 23% and myocardial infarction by 18% [2] (Table 1).

#### 3.1.1. After acute coronary syndromes (ACS) (class I grade A)

The benefits of physical activity are proven in secondary prevention for all coronary patients after ACS (ST-segment elevation myocardial infarction or non-ST-segment elevation myocardial infarction) [7–10]. The exercise capacity under treatment can be assessed from the third day if there are no complications, and it should be symptom limited. Monitoring is recommended during the first few training sessions [5]. The risk of stent thrombosis during cardiac rehabilitation is very low, estimated at 0.08% [11]. In addition, starting exercise training early reduces ventricular remodelling [12].

Exercise training includes endurance sessions, with continuous and/or interval training. Although still a topic of debate, to date, no difference has been observed between these two endurance methods in terms of prognosis [13]. Resistance training is also recommended [5].

Cardiac rehabilitation in an outpatient setting should be preferred.

#### 3.1.2. Chronic coronary syndrome (class I grade A)

Cardiac rehabilitation is recommended to improve exercise capacity and QoL and counteract risk factors, optimize adherence and compliance, reduce relapses and delay the atherothrombotic process [14–16]. Assessment of exercise capacity, limited by symptoms, can be undertaken without delay after angioplasty and allows the optimization of medical treatment. Training aims to delay the ischaemic and/or angina threshold. Cardiac rehabilitation in an outpatient setting should be preferred.

#### 3.1.3. Coronary dissection (class IIa grade C)

Coronary dissection is not a very frequent disease (4% of ACS). Progressive exercise training (without Valsalva manoeuvre), at the level of first ventilatory threshold (VT1) improves exercise capacity and reduces the risk of relapse [17].

### 3.2. Heart surgery

Early referral to cardiac rehabilitation is preferable (Table 2). It is essential that a surgical report be included in the patient records transferred to the rehabilitation department. Attentive monitoring of the clinical status allows early detection of any infectious complications (scar infection, unexplained fever or inflammation). Pericardial effusion requires regular reassessment until its resolution as the risk of secondary tamponade remains possible. Nonsteroidal anti-inflammatory or colchicine treatments have not proven their efficacy [18]. Supraventricular arrhythmia is frequent but is not a contraindication for cardiac rehabilitation if the heart rate (HR) is controlled. Any thromboembolic complication (postoperative phlebitis, intraventricular thrombus) requires a temporary break in exercise training. The level and type of exercises must be adapted taking into account sternotomy, the state of surgical

**Table 1**  
Indications of cardiac rehabilitation in coronary disease (non-surgical).

	Objective	Level of proof Class	Degree of evidence Grade
STEMI or NSTEMI	Reduction in mortality and recurrence	I	A
	Early (< 30 days) improved remodelling	Ila	B
Chronic coronary syndrome including angioplasty	Prefer outpatient treatment	I	A
	Reduced progression of the atherothrombotic process	I	A
Coronary dissection	Improvement of exercise capacity	Ila	C

STEMI: ST-segment elevation myocardial infarction; NSTEMI: non-ST-segment elevation myocardial infarction.

**Table 2**  
Indications of cardiac rehabilitation in heart surgery.

	Objective(s)	Level of proof Class	Degree of evidence Grade
CABG	Reduced mortality and recurrent coronary events	I	A
Valve replacement or valvuloplasty	Improved exercise capacity	I	B
	Reduced morbidity and mortality		
Thoracic aortic surgery	Education on anticoagulants and prevention of endocarditis		
	Improve exercise capacity	Ila	B
Pre-surgery	Under blood pressure monitoring during effort		
	Improvement of clinical condition, preparing surgery	Ilb	B
TAVI	For patients with multiple comorbidities		
	Correct sedentarity Improve QoL	Ila	B

CABG: coronary artery bypass surgery; TAVI: transcatheter aortic valve implantation; QoL: quality of life.

scars, eventual anaemia and postoperative pain. Combined exercise training (endurance, resistance and respiratory) is recommended.

**3.2.1. Coronary artery bypass graft surgery (class I grade A)**  
Improvement of prognosis, exercise capacity and QoL [19–21] have been demonstrated. Cardiac rehabilitation favourably influences the return to work.

**3.2.2. Heart valve surgery (class I grade B)**  
It is recommended that all patients undergoing heart valve surgery be offered an exercise training programme. Early rehabilitation is effective and risk-free after valvuloplasty or valve replacement [22,23]. The benefits in terms of exercise capacity are similar to those for bypass surgery, with improved exercise tolerance and reduced morbidity and mortality [21,24]. Patient education should target anticoagulant treatment, self-measurement of international normalized ratio (INR) (for relevant patients) and prevention of endocarditis [25].

**3.2.3. Thoracic aortic surgery (class IIa grade B)**  
Cardiac rehabilitation after surgery for aortic dissection provides functional benefits. It is well tolerated at a moderate intensity when systolic blood pressure during training is maintained below 160 mmHg (expert consensus) by avoiding efforts with a strong isometric component [26,27]. By analogy, a similar protocol can be considered after surgery for aortic aneurysm [28].

**3.2.4. Pre-surgery period (class IIb grade B)**  
Patient management in the form of education and/or cardiovascular rehabilitation can be offered to patients with multiple comorbidities (in particular, morbid obesity, respiratory diseases) to reduce the length of hospital stay after surgery or to limit post-operative complications or depression [29,30].

**3.2.5. Percutaneous valve repair**  
A cardiac rehabilitation programme should be proposed after percutaneous valve repair.

After transcatheter aortic valve implantation (class IIa grade B), it can correct the deleterious consequences of sedentarity (time spent sitting) in patients and improve QoL [31,32]. The patients involved are often older, frail and have numerous comorbidities. The same recommendations probably apply after percutaneous mitral and tricuspid valve repair, although we currently lack scientific data [33].

**3.3. Heart failure (HF)**

Cardiac rehabilitation is part of the therapeutic arsenal for patients with HF [3] (Table 3). It can start as early as possible after an exacerbation or at any time in a patient with chronic HF [34,35].

**3.3.1. HF with reduced ejection fraction (class I grade A)**  
The cardiac rehabilitation programme must include at least: personalized exercise training, a specific patient education programme, drug titration and management of comorbidities (iron deficiency, diabetes, sleep apnoea, depression, cachexia, etc.) [5,36,37].

To assess the physical capacities and limitations of each individual patient, a cardiopulmonary exercise test (CPET) should be performed before starting the exercise training programme. For patients with the most severe disease (New York heart Association functional class IIIb), it is recommended that the programme be started in a hospital setting, before considering outpatient management. It is often necessary to extend the duration of the programme beyond what was initially planned.

A regular reassessment of physical performance is recommended (e.g. ‘mid-way’ CPET).

**Table 3**  
Indication of cardiac rehabilitation in heart failure and heart transplantation.

Heart failure	Objective(s)	Level of proof Class	Degree of evidence Grade
Reduced EF	Reduction of readmissions Trend for improved prognosis Improved exercise capacity and QoL	I	A
Preserved EF	Reduction of readmissions Improved QoL	Ila	B
Mild alteration of EF	Identical to reduced EF	I	A
Resynchronization	Improved exercise capacity and QoL	I	B
Left ventricular assist device	Improved exercise capacity and QoL Centres with relevant expertise	I	B
Heart transplantation	Improved prognosis, exercise capacity Centres with relevant expertise	I	A

EF: ejection fraction; QoL: quality of life.

Endurance training protocols use continuous and/or interval intensity exercise (interval training is particularly useful for patients with the lowest fitness levels) [5,37]. Active resistance training such as targeted muscle reinforcement [1,38,39] and inspiratory muscle training [5,40,41] are recommended.

Provided the exercises are properly adapted, the intensity is progressively increased and there is regular screening for any sign of decompensation, the risks associated with rehabilitation are very low. The effects on prognosis are favourable, with a 30% reduction in hospital readmission and a beneficial mortality trend [42–44]. The improvement of exercise capacity and the reduction in symptoms contribute to improving QoL. Non-responders (improvement in  $VO_2$  peak < 6–10% despite an appropriate programme) and non-compliant patients have a poorer prognosis [45–47]. Patient education has a major role here, making it possible to reduce readmissions (often linked to dietary or therapeutic compliance errors).

### 3.3.2. HF with preserved ejection fraction (class Ila grade B)

Some studies have shown the benefits of cardiac rehabilitation programmes in terms of QoL, recovery of autonomy and reduction in readmissions, with improvements in exercise capacity similar to those observed in patients with reduced ejection fraction [48–50].

### 3.3.3. Heart failure with moderately reduced ejection fraction

Few studies have specifically examined this population [51]. We generally consider that the indications and the results are similar to HF with reduced ejection fraction.

### 3.3.4. Cardiac resynchronization therapy (class I grade B)

Cardiac rehabilitation potentiates the effects of resynchronization. Indeed, the peripheral improvements as a result of training are complementary, explaining the additional gain in exercise tolerance [52–54]. Therapeutic education should focus on ‘living with’ the implanted device.

### 3.3.5. Left ventricular assist device (class I grade B)

Left ventricular assist devices are implanted as a bridge to transplant, another therapeutic decision or as a destination therapy. In all cases, it is a preferential indication for cardiac rehabilitation [55–57] related to physical deconditioning. Patient education must cover device and anticoagulant treatment management. This type of complex rehabilitation requires highly technical specially trained centres working in close collaboration with the surgical team. The advantages are similar to those for rehabilitation following a heart transplant (see Section 3.4) [58].

### 3.4. Heart transplantation (class I grade A)

Cardiac rehabilitation following heart transplantation presents some specificities linked to the surgery, the patient’s immune status and the psychosocial impact (Table 3). The immunosuppressive therapies (immunosuppressants, corticosteroids) have some muscle toxicity that can restrict the spontaneous return to physical activity.

In the first 3 months, cardiac rehabilitation is subject to monitoring for potential complications. Consequently, the exercise training should be gentle at first and then progressive. It should be guided by CPET and the patient’s perceived exertion feeling (Chronotropic incompetence due to the denervation means that heart rate is not a suitable monitoring parameter) [59,60].

A recent meta-analysis indicated a beneficial effect of training in the short-term, with additional gains with interval training compared to continuous training [61]. Cardiac rehabilitation in this context takes longer [62–64].

Patient education must focus primarily on anti-rejection treatments (immunosuppression), the prevention of complications linked to reduced immunity and to cardiovascular risk factors. Psychological support and help with socio-professional reintegration are particularly important in this context.

### 3.5. Peripheral artery disease (class I grade A)

Supervised or home-based rehabilitation [5] helps increase the pain threshold, distance, duration and speed of walking as well as improving QoL (Table 4). However, supervised rehabilitation provides greater benefits than home-based training [65]. Indications for rehabilitation in patients with peripheral artery disease are:

- asymptomatic with ankle-brachial systolic pressure index < 0.9;
- intermittent claudication or chronic permanent ischaemia;
- after revascularization.

Prior to rehabilitation, the patient should undergo assessment of walking ability (treadmill test, 6-minute walk test, etc.) and screening of associated diseases (including cardiovascular). For patients with a very limited walking capacity, a stress test can be performed on an arm ergometer [66].

Walking on flat terrain or a treadmill is the basic exercise (Table 5 [5,67–70]). Other types of exercise may be recommended in complement walking or in patients unable to walk, e.g. upper-body exercises, muscle strengthening, analytical exercises of the lower limbs. Walking in warm water is also beneficial [71]. Patient education and treatment of risk factors are essential in this very high-risk population [72,73].

Amputees require specialized management to deal with their prostheses. Following revascularization surgery, scar tissue must

**Table 4**  
Indication of cardiac rehabilitation in peripheral artery disease and other diseases.

	Objective(s)	Level of proof Class	Degree of evidence Grade
Peripheral artery disease	Improved limping, range and speed of walking QoL	I	A
ICD	Improve exercise capacity and reduce risk of arrhythmias With or without other rehabilitation indication	I	B
Congenital heart disease	Improve exercise capacity Postoperative or in case of physical deconditioning	IIa	B
Pulmonary hypertension	Improved exercise capacity and QoL	IIa	B
Hypertrophic cardiomyopathy	Improved exercise capacity, improved symptoms and QoL	IIa	B
Atrial fibrillation	Significant obstruction and symptoms Improved symptoms, QoL and reduced relapses	III IIb	C C
Myocarditis	Improve exercise capacity	IIb	C
High cardiovascular risk	Outside the acute inflammatory period Cardiovascular disease prevention As an outpatient	I	A

ICD: implantable cardioverter-defibrillator; QoL: quality of life.

**Table 5**  
Supervised exercise training programme in patients with peripheral artery disease [5,67–70].

Exercise characteristics	Walking on a treadmill or flat terrain under supervision of an exercise physiologist
Frequency	3–5 times/week
Duration of each exercise session	Approximately 30 minutes
Intensity	Alternating walking phases causing moderate or intermediate claudication pain and recovery phases. A gradual progression to more vigorous exercise intensity in line with the patient's capacity may be proposed
Duration of programme	At least 12 weeks

be accounted for and training on a cycle ergometer should be avoided in case of arterial anastomosis in the Scarpa femoral triangle region. After the initial phase of rehabilitation, patients must engage in a life-long daily walk lasting at least 20 minutes to maintain the benefits.

### 3.6. Other indications

#### 3.6.1. ICD (class I grade B)

Patients with ICDs often have another indication for cardiac rehabilitation (ischaemic cardiopathy, HF, etc.) but some patients are implanted in primary arrhythmogenic cardiopathies (Table 4). These patients should be referred to cardiac rehabilitation with the objective of gaining assurance during physical activity and benefiting from specific therapeutic education [74,75].

In patients with HF, there is no increase in the risk of ventricular arrhythmia during exercise [76–78]. The heart rate zone of programmed therapies must be known to train the patient to 10–20 beats below this threshold.

Gym and/or training movements involving the upper body should be performed carefully in the weeks following implantation to prevent any complications at the level of the surgical site and probes.

The use of electrostimulation must be discussed with the implantation centre.

A wearable cardioverter defibrillator is often recommended in case of severe left ventricular dysfunction while waiting for the

decision for definitive implantation. It is compatible with rehabilitation activities and must not be withdrawn during exercise training.

#### 3.6.2. Congenital heart disease (class IIa grade B)

The management of congenital heart disease has improved greatly, and almost 90% of children with congenital heart disease now reach adulthood [79]. Most of these patients have altered functional capacity, even those with less severe heart diseases (surgically repaired aortic coarctations, closed shunt, repaired valvulopathies, etc.) [80]. These patients have often been restricted from physical activities and must be offered exercise training [81–83].

Cardiac rehabilitation is recommended in patients with limited exercise capacity or after surgery, preferably in expert centres, in liaison with the referring congenital cardiology team.

A CPET is recommended [83,84]. Training should consider the risk of arrhythmias and potential oxygen desaturation.

For adolescents, French regulations allow their treatment in adult structures from the age of 16 years (a declaration must be made to the tutelary authorities). Hybrid or alternative programmes (gamified, outpatient, tele-rehabilitation) appear particularly suitable for this population [80].

#### 3.6.3. Primary pulmonary hypertension (class IIa grade B)

Until the start of the 2000s, pulmonary hypertension was a contraindication for exercise training. Since 2015, European guidelines recognize a beneficial effect on exercise capacity, muscle function and QoL, and possibly on right ventricular function, as well as pulmonary haemodynamics [85,86]. The 2018 consensus meeting confirmed the advantages of exercise training in patients with severe pulmonary hypertension [87].

The exercise training relies on a tailored and supervised physical exercise programme in expert centres, and presents no risk of serious adverse events in patients who have been stable for at least 2 months. The training intensity is around 50–60% of the maximum workload achieved during the initial assessment, keeping saturation above 85–90%. Nasal oxygen therapy can be provided as necessary and/or for patient comfort. The heart rate during training should be maintained at around 60–80% of the maximum heart rate reached during the initial assessment.



### 3.6.4. Hypertrophic cardiomyopathy (class IIa grade B)

Exercise training is not always contraindicated except in patients presenting a risk based on the European Society of Cardiology (ESC) hypertrophic cardiomyopathy score [88]. It is recommended that patients be assessed by a CPET. In this population, specific attention should be paid to symptoms, blood pressure adjustment and arrhythmias [89].

### 3.6.5. Laminopathies and arrhythmogenic right ventricular cardiomyopathy

High-intensity or prolonged physical activity is contraindicated for these forms of heart disease. Cardiac rehabilitation can be offered at low to moderate intensities (below VT1) [88].

### 3.6.6. Atrial fibrillation (class IIb grade C)

Atrial fibrillation is not a contraindication for stress testing or training. On the contrary, improvements to atrial fibrillation symptoms, QoL and exercise capacity have been shown after cardiac rehabilitation, without adverse events. A few studies have shown a reduction in atrial fibrillation burden, although mortality remained unchanged [90,91].

### 3.6.7. Myocarditis (class IIb grade C)

Exercise training is not recommended while inflammation persists. A return to regular activity is permitted, under monitoring, after stabilization. However, high intensities are not recommended for 3–6 months, in line with the European [88] and American [92] positions.

### 3.6.8. High cardiovascular risk (class I grade A)

With a view to primary prevention [1], all patients with a high cardiovascular risk must have access to recommended treatments and behavioural changes including therapeutic education and dietary advice, help with smoking cessation and engaging in regular physical activity. Management in an outpatient cardiac rehabilitation structure makes it possible to assess and initiate a programme to improve lifestyle habits, which should subsequently be pursued in appropriate structures (e.g. diabetes trajectory, obesity management, sports health).

## 4. Contraindications for exercise training

There are few contraindications to exercise training and they are often temporary. They are generally similar to those for exercise tests (Table 6) [93,94].

## 5. Assessment and risk stratification

### 5.1. Initial review [5,95]

The admission to a cardiac rehabilitation programme is validated by the cardiologist in charge of the programme following a request including an exhaustive report. The clinical assessment must include:

- a description of the symptoms and the complete physical examination;
- the search for comorbidities: chronic obstructive pulmonary disease (COPD), anaemia, kidney failure, orthopaedic issues, frailty, etc.;
- the search for, and assessment of, cardiovascular risk factors: smoking and addictions, high blood pressure, diabetes, dyslipidaemia, overweight/obesity, physical inactivity/sedentarity, family history, psychosocial risks and symptoms/non-traditional

**Table 6**  
Contraindications for exercise training.

Absolute contraindications	Relative contraindications (as assessed by the cardiologist)
ACS $\leq$ 3 days or non-stabilized	Stenosis of the left main coronary artery
Decompensated HF	Ventricular aneurysm
Severe, uncontrolled ventricular rhythm disorders	Supraventricular tachycardia with poorly controlled ventricular rate
Presence of an intracardiac thrombus with a strong risk of embolism (mobile, recent and/or untreated with anticoagulants)	High-degree or complete acquired heart block
Pericardial effusion, moderate to severe and/or with a haemodynamic impact	Recent stroke or TIA
Recent thrombophlebitis with or without pulmonary embolism with moderate to high risk of recurrence according to ESC guidelines [94]	Severe anaemia (haemoglobin < 9 g/dL), significant electrolyte imbalance, uncontrolled hyperthyroidism, etc.
Severe AND symptomatic obstacle to left ventricular ejection	Resting blood pressure > 200/110 mmHg (adapt for patient's age)
Any evolutive inflammatory and/or infectious disorder (including initial-phase myocarditis)	
Evolutive aortic dissection	
Inability to perform physical exercise	
Refusal by the patient	

ACS: acute coronary syndromes; ESC: European Society of Cardiology; HF: heart failure; TIA: transient ischaemic attack.

risk markers (hormonal factors, migraine with aura, erectile dysfunction, pollution, symptoms of breathing respiratory disorder, etc.).

It is also important to assess the patient's motivation and their psychosocial condition, and medication conciliation must be performed. Complementary tests must include at least:

- resting electrocardiogram (ECG);
- recent transthoracic echocardiography;
- biological tests including complete blood count, cholesterol, glucose, glycated haemoglobin (HbA1c), natriuretic peptides, renal and hepatic functions, creatinine kinase, etc.

Except for contraindications (see Table 6), the aim of an exercise test [93] is to stratify the risk of evolution of the patient's condition and to prescribe a personalized exercise-based cardiac rehabilitation programme. The exercise test must:

- comply with the safety protocols and criteria defined for exercise tests [95]. These tests are habitually performed while the patient is taking their medical treatment;
- be limited by the symptoms or sometimes by a maximal HR (patients with implantable defibrillators) or even by maximum systolic blood pressure determined by the operator (i.e. early follow-up for aortic dissection or surgery for aortic aneurysm).

If possible, a CPET should be preferred for all patients. Results can be used to assess prognosis and to determine the ventilatory thresholds to guide the personalization of the subsequent exercise training programme. An intermediate exercise test is indicated in case of new symptoms or significant changes in therapy, or to review prescriptions based on changes in the patient's condition. A final stress test objectively assesses the patient's exercise capacity and is a guide for phase III training. Changes in exercise capacity also have a prognostic value.

A 6-minute walking test can be used to assess the patient's adaptation to sub-maximal efforts; it is highly recommended if a conventional stress test is not performed. This type of test is also relevant in patients with HF.

**Table 7**

Proposal for the start of a 'standard' exercise training programme (initially based on HR or workload; later, preferably based on a perceived scale). The duration and intensity of exercises must progress and be regularly re-assessed.

Type (criteria)	Frequency	Intensity		Time
		Moderate	Interval training	
Endurance (VT1–VT2 <sup>a</sup> , max HR, HRR <sup>b</sup> , exercise HR <sup>c</sup> , Borg)	3–6 times per week	Warm-up; continuous intensity; recovery 40–59% VO <sub>2</sub> peak; VT1 (power, HR); exercise HR <sup>c</sup> according to Karvonen formula Borg 12–14	Warm-up; alternate periods of high- and low-intensity; recovery 1 minute HIP and 2 or 3 minutes LIP, adapted based on tolerance and variations in HR during recovery HIP: 70–90% VO <sub>2</sub> peak power or max HR or VT2 LIP: 30% max HR or ≤ VT1 (power or HR) Borg 14 (LIP); 16–17 (HIP)	20–45 minutes
Resistance (1-RM <sup>d</sup> , OMNI-RES <sup>e</sup> )	2–3 times per week	30–70% of 1-RM <sup>d</sup> (upper body) 40–80% of 1-RM <sup>d</sup> (lower body) 10–15 reps OMNI-RES <sup>e</sup> : 5–8		≥ 20–30 minutes

1-RM: one-repetition maximum; CPET: cardiopulmonary exercise test; HIP: high-intensity period; HR: heart rate; HRR: heart rate reserve; LIP: low-intensity period; max: maximum; reps: repetitions; VT1: first ventilatory threshold; VT2: second ventilatory threshold.

<sup>a</sup> Values measured during CPET: VT1, VT2 and VO<sub>2</sub> peak.

<sup>b</sup> HRR: max HR – RHR.

<sup>c</sup> Exercise HR = resting HR + (HR reserve × K). K = 0.6 (or 0.8 if the patient is treated with beta-blockers).

<sup>d</sup> Assessment of maximal strength by 1-RM corresponding to the 1-RM for an exercise.

<sup>e</sup> OMNI-RES scale: perceived muscular exertion.

Assessment of the strength of large muscle groups is recommended to guide resistance training [5,96].

Other explorations may also be necessary, including:

- measurement of the ankle brachial index;
- arterial echo-doppler (carotid, abdominal and lower limb arteries);
- Holter-ECG recording;
- ambulatory blood pressure monitoring;
- nocturnal polygraphy in case of evocative symptoms or systematic screening for sleep disorders;
- pulmonary function test;
- magnetic resonance imaging.

## 5.2. Risk scores

Several risk scores have been proposed in cardiac rehabilitation, although they all have a low predictive value [97]. The most frequently retained risk stratification factors are a low exercise capacity (calculated in metabolic equivalents of task [METs] or VO<sub>2</sub> peak), HR abnormalities and severe arrhythmias, effort-induced ischaemia and altered ejection fraction, followed by blood pressure profile abnormalities during effort and post-surgical complications. The presence of one of these elements can be used to adapt the training intensity, follow-up and monitoring of patients.

## 6. Exercise training

### 6.1. Modalities for training [37,96,98–101]

Exercise training must be prescribed on an individual basis after an initial check-up including an assessment of exercise capacity, risk stratification, behavioural characteristics and a discussion of objectives with the patient. The training protocol should be adapted to the context (recent sternotomy, implantation of a pacemaker or cardiac defibrillator) and non-cardiological pathologies

or interventions. Ideally, this training should combine endurance, resistance, flexibility and balance.

Endurance training can be undertaken in various ways, including plateau at continuous sub-maximal intensity and interval training, characterized by alternating high-intensity effort and active recovery phases. Several combinations are possible, varying the intensity, the duration of effort and recovery. Muscle strengthening is achieved with dynamic resistance using weights, elastics bands or on weight machines. During these sessions, main muscular groups should be involved and the type of movement to be repeated should be diversified. Respiratory training, individually or as a group, completes the programme. Other physical activities can also be proposed, including gymnastics, training in water, dance, balance and flexibility exercises, yoga, Tai Chi, etc. Electromyostimulation can be used in patients with a very altered physical condition, excluding those with an ICD, and with specific monitoring implemented for patients requiring cardiac stimulation [102].

Fitness equipment includes treadmills, various types of cycle ergometers (sitting, lying, arm, elliptical), rowing machines, walking poles, resistance training on benches or machines, free weights, elastics, etc. Connected devices with a heart rate monitor, pedometer or gamification can be used.

### 6.2. Organization of training sessions

Telemetric monitoring is recommended during the first few sessions and may be continued depending on the patient's risk profile. Exercise training should be prescribed according to the frequency, intensity, time and type (FITT) principle (Table 7). At least 20 sessions are recommended to see significant improvements in functional capacity. However, the number of sessions should be adapted to the patient's situation: sometimes more sessions are required for the most seriously affected patients (HF, transplant patients) or those who are very unfit; fewer sessions may be required for patients without deconditioning.

### 6.2.1. Endurance

The programme must take place on 3–6 days/week. Each session includes a warm-up period lasting 5–10 minutes, a 20–45-minute exercise period and a recovery period lasting at least 5 minutes.

Continuous moderate-intensity endurance: this corresponds to aerobic training. The intensity is best determined by the workload and HR at VT1. If VT1 data are not available, the intensity should be set to 40–59% of the VO<sub>2</sub> peak attained. The exercise HR can also be determined using the Karvonen formula (exercise HR = resting HR + [K × HR reserve], where K = 0.6 if no bradycardic agents or 0.8 if bradycardic treatment) and/or 12–14/20 on the Borg scale.

Interval training: this training associates aerobic phases with a low workload and more intense phases leading to the production of lactates. The intensities must account for the ventilatory thresholds (VT1 and VT2). For the intense phases, at 70–80% of peak VO<sub>2</sub>, 75–90% of max HR or Borg score 14–16 [1].

The intensity is modulable over the programme depending on cardiac and muscular tolerance, as well as the patient's psychological progress, and must be guided by the Borg scale with the objective of regular increases in intensity.

### 6.2.2. Resistance

The one-repetition maximum (1-RM) should be assessed (generally derived from the 10-RM technique) or dynamometry performed.

Resistance training should be prescribed at an intensity of 30–70% of the 1-RM for the upper body and 40–80% of the 1-RM for lower-body exercises. During initial prescription, aim for 10–15 repetitions in a single series, increasing over the course of the programme.

Duration of sessions: at least 20–30 minutes (preferably 45–60 minutes) per session.

Two to 3 sessions per week.

Progression guided by the OMNI-RES scale [103], on which patients rate their perceived exertion from 0 (extremely easy) to 10 (extremely hard).

The most recent studies suggest that higher intensities should be preferred over higher number of repetitions (i.e. 70%, 3–10 repetitions, by muscular groups).

### 6.3. Physical activity after cardiac rehabilitation

Maintaining physical activity and reducing sedentary are the main public health objectives aiming to prolong and improve the long-term results of cardiac rehabilitation. Physical activity should be individually prescribed and must also avoid sedentary behaviour. Prescribed as progressive, regular exercise in an adapted form to encourage strong and prolonged adherence, it is based on the results of the exercise test performed at the end of the cardiac rehabilitation programme determining the physical capacity and safe level of activity.

Five 30-minute sessions of moderate-intensity endurance activity or 75 minutes per week of more vigorous activity or a combination of the two, associated with 2–3 muscle-strengthening sessions per week are the basis of the minimum recommendations [1]. For the least active patients, this level will be progressively attained and the reduction in sedentary time is also a priority goal. The selected activities must be easy to realistically integrate into the patient's life, making physical activity part of their daily routine. Setting and reassessing objectives, using an activity tracker or a heart rate monitor for self-monitoring can help improve practice in the mid- to long-term.

Patients can be referred to several types of structure for this type of support (the French Cardiology Federation 'Heart and health clubs', 'sport-health'-accredited fitness centres). It is recommended that cardiac rehabilitation centres make their equipment avail-

able for phase III, supervised by physiotherapists and/or adapted physical activity coaches, who have been taught to create training programmes. Medical certificates can, if necessary, stipulate some precautions. It is recommended that the building be equipped with an automatic external defibrillator.

A leisure sports activity will be recommended for patients with an appropriate technical level for the particular physical activity and whose clinical status is compatible with its practice [88]. The patient must be capable of self-monitoring and be able to adapt their practice to the environmental conditions (temperature, pollution, altitude and setting).

Sports competitions should not be systematically contraindicated. For example, for low-risk patients, in line with European recommendations [88], the decision should be made with the patient (risk/benefit ratio). This permission is reviewed annually during a complete cardiological check-up.

## 7. Therapeutic education programme

It is recommended that every cardiac rehabilitation structure propose one or more therapeutic patient education programmes dealing with the disease and the related warning symptoms, nutritional aspects, recommendations around physical activity, assistance and/or counselling on smoking cessation, stress management, treatment management, prophylaxis to prevent infectious endocarditis, etc. (Table 8).

Every therapeutic patient education programme should be structured according to the current legal recommendations and meet the quality criteria defined by the Haute Autorité de santé (HAS; French National Authority for Health). The decree of December 2020 sets out the specifications, the required competencies for each person involved (and the coordinators), the principle of declaration to the relevant regional health authorities and the quadrennial assessment performed by the team [104,105].

Group workshops are facilitated by a multidisciplinary rehabilitation team trained in therapeutic patient education and competent in the relevant sector. Group activities are complemented by individual sessions [106]. Considered and coordinated organization

**Table 8**  
Educational themes (non-exhaustive list).

Theme	Factors
Knowledge of the disease	The heart and how it works
	Cardiovascular risk factors
	Diseases (coronary heart disease, HF, arterial disease, etc.)
	Cardiological tests
	Warning signs (chest pain, breathlessness, etc.)
	Self-measurement methods (blood pressure, glycaemia)
	Pharmacological treatments
	Interventional and surgical treatments
	Emergency procedures
	Cardioprotective diet
Nutrition	Reading labels
	Detecting hidden salt
	Information on Nutriscore (advantages, limitations)
Physical activity	Combatting sedentary
	What exercises to do and not to do
Miscellaneous	Getting to know the markers of effort intensity
	Managing endurance training
	Management of VKA use
	Prevention of endocarditis
	Living with a cardiovascular implantable electronic device
Managing daily activities	Living with immunosuppressive therapy
	Travel, sex, driving, etc.

HF: heart failure; VKA: vitamin K antagonist.



**Table 9**  
Cardioprotective diet (modified from the ESC recommendations and the PNNS [1,110]).

---

At least 5 portions of fruit and vegetables per day
1 starchy food at every meal (whole cereals recommended)
Eat unsalted nuts (1 handful per day)
2–3 dairy products per day (vary the type: milk, cheese, yoghurt, cream cheese)
Preference for poultry or rabbit and limited consumption of red meat (2 portions/week)
Limit processed meats (deli-meats) (2 portions/week, equivalent to 150 g/week)
Eat fish at least twice per week (including one portion of oily fish)
Eat pulses at least twice per week (source of fibre and protein)
Use virgin olive oil and rapeseed or walnut oil every day
Avoid sweet drinks and foods
Drink coffee, tea, cocoa (rich in polyphenols)
Favour home-made food (limit ultra-processed foods)
Limit alcohol consumption ( $\leq 10$ standard units per week, $\leq 2$ standard units per day)
Limit salt to $< 5$ g/day (table salt, ultra-processed foods) especially if high blood pressure or HF
Use herbs and spices abundantly

---

ESC: European Society of Cardiology; HF: heart failure; PNNS: Programme National Nutrition Santé (French National Health and Nutrition Plan).

is necessary, with regular readjustments during multidisciplinary consultations.

### 7.1. Nutritional education

The dietary model with the best proven efficacy for the prevention of cardiovascular disease is a Mediterranean-type diet [107–109] (Table 9 [1,110]). The various components include a nutritional survey [111], individual and/or group dietary education and promotion of a Mediterranean diet. Advice should be adapted to the context (hypertension, diabetes, obesity, HF, renal failure, malnutrition).

### 7.2. Smoking cessation

Smoking is a major cardiovascular risk factor [112] and smoking cessation is one of the most effective secondary prevention strategies [113]. Management of this risk factor must be part of any cardiovascular rehabilitation programme [114]. The institution must provide, if possible, a dedicated consultation with a tobacco specialist, or at least a member of the medical or nursing team who has completed specific training (Inter-University Diploma). The paramedical team plays an important role in this management. The patient must be informed of the crucial importance of quitting smoking and be able to take advantage of proven effective treatments [115].

First-line treatment with nicotine replacement products must be given in the intensive care unit [116], adjusting the dose rapidly to completely cover the withdrawal symptoms. To do so, patches and oral absorption forms (gummies, lozenges) should be combined [117]. The dose will then be progressively reduced over at least 3 months, or more if necessary. Nicotine replacement products are 100% covered by the French social insurance system for patients with a long-term disease. Varenicline (Champix®) can be used if necessary as a second-line treatment, and is also covered by the health system.

Cognitive-behavioural therapies have also been validated. Anti-anxiety and/or antidepressant treatments may be necessary for a period, but anxiety-depression disorders, maintained by smoking, generally improve upon cessation of smoking [118].

Even though the use of e-cigarettes (vaping) cannot be specifically recommended in cardiac patients, it is nevertheless less toxic than regular cigarettes (no carbon monoxide). However, all tobacco

consumption must be stopped as double use (vaping-smoking) provides no benefit. In the absence of long-term data, it should be stopped as early as possible [119]. Heated tobacco and nicotine pouches, new lures from the tobacco industry, should certainly not be considered as a step towards cessation and should be discouraged [120].

Prolonged follow-up should be provided, in close cooperation with the cardiologist and the general practitioner, who should be alerted. The patient should leave the rehabilitation centre with a prescription for treatment to help with smoking cessation, a follow-up appointment and a report that mentions the treatment started and the elements to be monitored.

### 7.3. Treatment for addictions

Beyond tobacco and alcohol, several recent studies have shown that use of illicit drugs including cannabis, cocaine, heroin and opioids, amphetamines and methylenedioxy-methylamphetamine (MDMA or ecstasy) could be a real factor for poor prognosis in patients with established heart disease [121,122]. With the objective of discontinuing use, the process starts with abstaining from consumption, completely and for a sufficiently long time to recover a normal life. Psychological, psychiatric, social and family follow-up are recommended. The care protocol often includes a programme of workshops and therapeutic meetings. It is essential to monitor the patient's addiction trajectory, as any relapse entails an additional risk of cardiovascular and heart rhythm events that must be diagnosed and managed.

### 7.4. Education on antithrombotic treatments

Given the risks inherent to this treatment, patient education plays a determinant role in the correct use of VKAs, direct oral anticoagulants and antiplatelet therapies [106]. It is recommended that all centres provide education on these antithrombotic treatments in the form of structured sessions, distribution of documentation (monitoring log and up-to-date completed treatment cards). The patient must know the name and dose, indication and planned duration of their treatment, the side-effects, what to do in case they forget or delay taking a dose (travel), what biomonitoring is required, how to detect overdosing (bleeding, anaemia, etc.) and any drug interactions [106]. For patients fitted with a mechanical artificial valve, it is recommended that the centre be accredited for training in self-measurement of INR [123].

### 7.5. Prophylaxis to prevent infectious endocarditis

European recommendations [124] limit antibiotic-based prophylaxis (Table 10):

- to three patient categories: fitted with any type of replacement valve, with a history of endocarditis and uncorrected or incompletely corrected congenital cyanotic heart disease (residual shunts);

**Table 10**  
Education on prophylaxis to prevent infectious endocarditis.

---

Provide information on prophylaxis (risks)
Deliver a specific card
Recommend strict dental and skin hygiene
Dental check-ups required twice a year
Disinfection of wounds
No self-medication with antibiotics
Discourage piercing and body art
Consult a doctor in case of persistent fever

---

- for a single situation presenting a risk: dental interventions affecting the gums or the periapical region or associated with perforation of the oral mucosa.

## 7.6. Daily life

### 7.6.1. Driving

The patient's aptitude for driving depends on their risk of loss of consciousness. The decree of 28 March 2022 sets out the list of medical disorders that are incompatible or compatible, with or without adaptations or restrictions, with the obtention, renewal or maintenance of the driver's licence, or that can lead to attribution of a limited-validity driver's licence [125]. Any doctor that expresses reservations to driving must inform the patient of the necessary steps to be undertaken with respect to the local authority's medical aptitude commission. The reasoned opinion of the rehabilitation department must be clearly set out in the patient's records and release notes, with the patient's full knowledge and approval.

Only drivers of heavy vehicles (or light vehicles with passenger transport) are required to undergo a medical aptitude test and to submit to regular examinations. According to the French labour code, aptitude for occupational driving can only be assessed by the occupational physician, based on the opinions of the cardiologist and the accredited doctor on the local authority's commission.

### 7.6.2. Travel

The advice must consider the severity and stability of the disease and the journey planned. All non-stabilized conditions (i.e. decompensated HF, early or complicated ACS, etc.) are contraindications for non-medical transport. Precautions to be taken in the case of flights or long trips relate to the following [126]:

- ACS less than 2 weeks before travel;
- coronary bypass less than 3 weeks before travel;
- HF;
- uncontrolled ventricular arrhythmias;
- recent thromboembolic disease;
- ventricular assistance;
- recent ICD as secondary prevention.

It is recommended to advise the patient as follows:

- take out travel insurance covering medicalized repatriation and annulation;
- take a summary of their medical history with them, translated into English if possible;
- carry a reference ECG trace;
- bring their last prescription with drugs listed by their international non-proprietary names (or translated into English if necessary);
- pack sufficient stock of treatment to cover the duration of their trip and a few extra days;
- always keep their treatment with them;
- make sure they have sufficient time in airports (boarding, transit, etc.) to minimize stress.

For trips to countries with specific environments, an appropriate physical condition and a minimum of 4 weeks of clinical stabilization are required if physical activity above 2000 m is planned; a stress test must show no symptoms of myocardial ischaemia, no arrhythmia and no haemodynamic instability [127]. However, altitude is not the only parameter to be considered, one should also consider the type of activity, climate conditions, individual 'technical' aptitude, etc. Methods to protect against extreme heat should be presented (hydration, appropriate clothing, etc.) and patients

should be advised against intense physical efforts in those conditions. If the trip is planned with the aim of participating in sporting activities, refer to the 2021 European recommendations [88].

### 7.6.3. Sexual activity

Sexual health is an important aspect of QoL [128] and must therefore be an integral part of patient management by the multi-disciplinary team involved in cardiac rehabilitation, and members should be appropriately trained. The team should be proactive, inviting patients to share their questions and experiences, and proposing appropriate solutions; psychological assistance should be available if necessary.

Sexual difficulties may arise in both sexes due to the disease, comorbidities and pharmacological treatments (beta-blockers, diuretics, blood pressure medication, etc.). Dose reduction or a change of therapeutic class can improve sexual function and/or compliance [129]. Phosphodiesterase inhibitors can be prescribed to men with a stable cardiovascular condition presenting a low risk of complications [130].

The risk of occurrence of a cardiovascular event during sexual activity is low, especially if patients are engaged in regular physical activity and have good functional capacity. Cardiac rehabilitation improves sexual health [131]. Patients with an exercise capacity of more than 3 METs who are asymptomatic can engage in sexual activity without notable risks. The American recommendations are more precise, but the elements have a low level of proof [132] (Table 11).

## 8. Treatment optimization

During cardiovascular rehabilitation is an ideal time to optimize and titrate pharmacological treatments in line with the recommendations for prevention of cardiovascular and other diseases [1]. Indeed, the duration of patient management and the return to normal exercise activity make it possible to tailor the treatment based on tolerance at rest and during effort [6,133]. In association with therapeutic education, this promotes improved adherence and compliance with treatment [134,135].

## 9. Psychosocial management

As psychosocial factors play a crucial role both before and after the onset of cardiovascular diseases [136], their management during rehabilitation is essential. Numerous psychosocial factors have an impact on the occurrence and prognosis of cardiovascular diseases: anxiety, depression, hostility, anger, D-type personality (combination of negative affect and social inhibition), posttraumatic stress disorder, occupational stress and its possible progression towards burn-out, isolation, lack of social support, low socioeconomic status and traumatic events in childhood [137–142]. In addition, a cardiovascular disease is likely to trigger psychological distress: stress, anxiety, depression and posttraumatic stress disorder [143]. Psychosocial factors have a variable impact depending on gender, and this notion must be considered during rehabilitation [144].

### 9.1. Psychological management

A psychosocial assessment is essential at the very start of rehabilitation. It can be facilitated using dedicated questionnaires (Hospital Anxiety and Depression, Beck Depression Inventory). The questionnaire developed by the ESC is validated as a simple rapid-screening tool [145]. A psychologist must be available during cardiac rehabilitation and an individual consultation is recommended. In collaboration with the care team, the psychologist

**Table 11**  
Recommendations related to sexual activity [132].

Recommendations	Level of proof Class	Degree of evidence Grade
Therapeutic management related to sexual activity must be offered to both men and women, considering the psychological dimensions and the individual wishes of patients	I	C
Engaging in sexual activity is reasonable in patients classed as at low risk of cardiovascular complications	IIa	B
Patients with a non-stabilized cardiovascular disease or who are symptomatic should not engage in sexual activity until their condition has stabilized and they have been appropriately assessed and treated	III	C
A cardiac rehabilitation programme and regular exercise training reduce the risk of cardiovascular complications during sexual activity	IIa	B
Patients with angina or who are incompletely revascularized must undergo assessment, therapeutic optimization and be stabilized before engaging in sexual activity	III	C
Sexual activity is reasonable in patients with HF who are stable in NYHA Class I or II	IIa	B
Sexual activity is inadvisable in patients with severe symptoms or decompensated heart failure (NYHA Classes III or IV) before therapeutic optimization and improvement to their symptoms	III	C

HF: heart failure; NYHA: New York Heart Association.

should contribute to the therapeutic education programme. In some cases, a second opinion from a psychiatrist may be requested. It is desirable that the psychosocial treatment report be included in the patient's release notes to encourage continued psychological support after cardiac rehabilitation. Management of psychosocial factors relies on four elements:

- therapeutic education;
- engagement with exercise training during rehabilitation (the therapeutic effect is considerable in case of anxiety-depression disorder);
- psychological management by personnel trained in the use of non-drug treatments: relaxation (yoga, sophrology), meditation, in particular mindfulness and cardiac coherence, cognitive behavioural therapy, hypnotherapy or eye movement desensitization and reprocessing, etc. [146,147];
- drug treatments can also be proposed (anti-anxiety or antidepressant treatments) if required after consultation of a psychiatrist [148,149].

## 9.2. Return to work

Return to work is one of the objectives of cardiac rehabilitation. The occupational activity, in terms of exercise and mental workload, will be assessed as soon as possible. Factors influencing the return to work include [150]:

- the type of heart disease and related functional status: the severity of the heart disease, presence of an implanted device, left ventricular ejection fraction, ventricular arrhythmia, exercise capacity [151,152]. These data will be communicated to the occupational physician via the patient;
- assessment of the workplace: any load-bearing activities and exertional effort, environmental constraints and general working conditions must be defined. During the assessment, the following parameters should be considered: duration of commute, sedentary work, shift work, working under high temperatures, working under cold temperatures and in humid conditions, work at altitude or at height, security positions. The specific case of driving is covered by the decree of 28 March 2022 [125];
- assessment of occupational stress: occupational stress can be assessed using two structured and validated questionnaire models. These are the Karasek model [153], which has been validated for manual labourers; and the Siegrist model, which is better adapted for managers (white collar workers) [154];

- job strain is defined by low decisional latitude and a high psychological pressure. It is an independent factor for the occurrence of a coronary incident and long-term relapse [155], and an indicator in favour of a later return to work.

In some specific cases, an occupational simulation may be proposed at the end of the cardiac rehabilitation. The opinion of the rehabilitation cardiologist on the return to work is important and must be recorded in the patient's release notes: possible date of return to work, any adaptations necessary, therapeutic part-time work, etc. The patient is encouraged to make an appointment as early as possible, and before the end of their sick leave, with the occupational physician for a 'pre-return medical assessment'.

## 10. Important populations

### 10.1. Patients with diabetes

Patients with diabetes (mainly type 2 diabetes) account for 20–30% of the overall population in cardiac rehabilitation [156]. They are characterized by a greater frequency of cardiovascular-associated risk factors, polyvascular disease and comorbidities. In addition, their initial exercise capacity is lower [156–158].

Regular exercise is part of the non-pharmacological treatment of diabetes (class I level A) on the same level as dietary advice [159], and it has numerous beneficial effects [160,161]: significant improvement in glycaemic control leading to a 0.7% reduction in HbA1c, on average; reduction in degenerative complications of diabetes; and a reduction in visceral fat. Regular exercise improves the cardiovascular risk profile and insulin sensitivity. It significantly improves the VO<sub>2</sub> peak, but this improvement is correlated with good glycaemic control during rehabilitation [162].

The current recommendations [5,160,161,163,164] suggest three courses of action: combat sedentariness, increase physical activity in daily life and undertake supervised, structured exercise and/or sports activities with a minimum weekly volume of 2.5 hours at moderate to high intensity, combining endurance exercises with muscle strengthening [164,165]. Activities to develop flexibility and balance as well as stress management can be added. Activities undertaken in water are interesting as they reduce the feeling of difficulty linked to the patient's weight and constraints on joints.

The reduction in glycaemia is correlated with the duration of endurance exercise sessions, with effects lasting beyond the end of the session. The effects of endurance on glycaemic control are time-

limited (around 30 hours), which explains the need for regularity in any physical activity [160].

Diabetes complications (retinopathy, kidney disease and neuropathy) are not contraindications for training, although patients with proliferative retinopathy should avoid overly intense activities. In parallel, the patient's glycaemia should be monitored in line with the recommendations [166], with a preference for self-measurement: before exercise, at the end of exercise, and 4–6 hours after exercise, with the aim of identifying hypoglycaemic events rapidly and preventing severe hypoglycaemia among patients treated with insulin or insulin-releasing compounds (sulfamides or glinides).

If the pre-exercise glycaemia is  $> 2.5$  g/L (13.9 mmol/L), urinary acetone should be measured, the hyperglycaemia should be corrected and the exercise training delayed. The rehabilitation team and the patient must know how to recognize symptoms of hypoglycaemia and what to do in case of emergency: stop the effort and consume a combination of simple and complex sugars.

Specific patient education aims to help patients to better understand their disease and the relation between glycaemic regulation anomalies and cardiovascular risk, to engage with their follow-up and monitoring for complications. Through educational modules, patients will become aware of the beneficial effects of physical activity, both in terms of glycaemia and of cardiovascular risks, which should motivate them to continue with their practice in the long-term.

Therapeutic patient education also contributes to optimal compliance by explaining the effects of the various (sometimes complementary) anti-diabetes treatments and familiarizing patients with those that can cause hypoglycaemia (sulfamides, glinides and insulin).

The psychological benefits of cardiac rehabilitation [167] promote active involvement of patients with diabetes in behaviour changes. The duration of cardiac rehabilitation allows optimization of the cardiologist/endocrinologist collaboration in particular for treatment adaptations in line with international recommendations.

An endocrinologist should be consulted if:  $HbA1c \geq 8\%$ , patients have severe/frequent hypoglycaemic events, newly-diagnosed diabetes to optimize treatment selection, introduction of treatment with glucagon-like peptide-1 analogues or sodium/glucose cotransporter 2 inhibitors in patients with diabetes already treated with sulfamides/glinides and/or insulin (increased risk of hypoglycaemia) [157,163,168].

Cardiac rehabilitation is also a crucial opportunity to screen for diabetes and prediabetes [157]. Indeed, it has been shown that the glucose monitoring performed on patients admitted to rehabilitation after an ACS who have an  $HbA1c$  level below 6.5% can identify a significant proportion of previously unidentified patients with glucose metabolism disorders (prediabetes) [168,169]. The patients identified during rehabilitation can then benefit from real, active and multifaceted management.

### 10.2. Cardio-oncology

This section covers patients with cancer and heart disease, cardiovascular risk factors and those who will be treated with cardiotoxic chemotherapy, in the absence of oncological contraindications. The benefits of exercise in cancer are increasingly understood: slowing of cancer progression, beneficial effects on fatigue and QoL, improved chemotherapy tolerance and reduced cardiotoxicity of chemotherapy [170,171]. Cancers and cardiovascular diseases share numerous risk factors (the cancer itself and its treatments are recognized as cardiovascular risk factors), and cardiac rehabilitation is recommended to compensate for these cardiovascular risk factors, and to reduce mortality in some cancers, particularly breast and colon cancer. The rehabilitation modalities

are identical to those for heart disease, although endurance training should be adapted to the oncological situation [172].

### 10.3. Older people

Older people are defined by the World Health Organization as those aged over 60 years, but in most studies subjects are considered older when aged over 65 years with comorbidities, or over 75 years. Despite the constant growth of this population (25%  $> 65$ -year-olds by 2050), prescription and participation in cardiovascular rehabilitation programmes remains low, particularly among women [173]. Nevertheless, beneficial effects in terms of maximum or sub-maximal effort tolerance, QoL, and survival are observed for older adults, with a reduction of 5-year mortality by 21–34% [174]. The objectives are mainly to improve autonomy, the main contributor to QoL in older patients with heart disease.

For the initial assessment, in addition to the standard check-up detailed in Section 5.1, a geriatric assessment – including at least comorbidities and psychosocial aspects, as well as measuring frailty – is necessary to validate the relevance and the modalities of the programme [175]. Patients should be referred to a cardiac rehabilitation institution specializing in cardiovascular diseases when the principal diagnosis is cardiological and they do not present prohibitive comorbidities, for patients capable of recovering or improving their autonomy in their day-to-day lives. For other patients, admission to an elderly care or polyvalent rehabilitation institution should be considered. Beyond the usual management through residential or outpatient services, additional modalities are being assessed to improve access to rehabilitation: home rehabilitation, tele-rehabilitation, hybrid solutions, etc. [176].

The decrease in muscular strength linked to sarcopenia is an independent risk factor for cardiovascular mortality: the combination of resistance training with aerobic exercise is recommended to improve muscular strength and endurance, and to preserve or restore autonomy and thus QoL [95,177,178]. Interval training is free from risks and at least as effective as continuous training [179]. Complementary practices (such as Tai Chi, Qi Gong) also have positive effects and are clearly adapted to this population.

Dietary advice should be adapted to older individuals (accounting for undernutrition and/or deficiencies) and – as for younger populations – lifestyle modifications must be undertaken.

The benefits of quitting smoking and controlling blood pressure are comparable to those obtained in younger populations.

### 10.4. Women

For women, cardiovascular rehabilitation is characterized as follows:

- women are under-represented in rehabilitation, regardless of age: after heart attack, 30% of men compared to 25% of women are referred to cardiac rehabilitation, although recent progress should be noted [180];
- barriers to cardiac rehabilitation are multiple: lack of interest, lack of information and prescription, fear of an ill-adapted programme, low family support, domestic and family activities considered a priority, lack of transport, etc.

The specific risk factors to be dealt with in patient education programmes for women are the following [181]:

- some traditional risk factors are more frequent (psychosocial stress, excess weight, sedentarity, etc.);



- other risk factors have a greater impact than in men (46% higher risk of fatal coronary heart disease with type 2 diabetes [182] or 25% higher risk of coronary heart disease with smoking [183]);
- in addition, specific risk factors linked to the various stages of women's hormonal or gestational lives must be added: combined contraception, pathological pregnancies, menopause and hormone replacement therapy.

Beneficial effects have been observed with cardiac rehabilitation on morbidity-mortality and on improvements in exercise capacity, even if differences based on sex and gender are noted (+2.2 MET in men vs. +1.7 MET in women) [184,185].

Women have a higher incidence of some cardiovascular diseases, such as coronary dissection, Takotsubo syndrome and myocardial infarction or ischaemia with non-obstructive coronary arteries. However, few studies are available on the effects of cardiac rehabilitation in pathologies more often affecting women, despite the recommendations of HAS [186].

### 10.5. Patients with comorbidities

#### 10.5.1. COPD

COPD is the disease most frequently associated with cardiovascular diseases [187]. It affects 5–10% of the French population aged over 45 years, among whom 1 million are symptomatic. Of all the respiratory disorders, this chronic respiratory disease is associated with the highest level of proof of efficacy of respiratory rehabilitation in the literature. Respiratory rehabilitation is indicated for all chronic respiratory diseases, whatever the severity, and must be prescribed for any patient who still has symptoms despite optimization of their pharmacological treatment. It is effective in reducing breathlessness and hospital readmissions, while also improving QoL and exercise tolerance [188].

In practice, according to the HAS, any adult over 40 years of age with a smoking habit of more than 10 packets/year who is eligible for cardiovascular rehabilitation should be offered a spirometry test and be referred to a pulmonologist for a check-up to optimize their treatment and assess the need for oxygen therapy during exercise [189].

The specificities of COPD evaluation require tobacco consumption and dietary status to be assessed; the exercise capacity should be evaluated based on a CEPT with monitoring of oxygen saturation [190]. The exercise test and the echocardiography will allow an informed decision on whether rehabilitation should be undertaken in a rehabilitation institution specializing in cardiology or pulmonology, depending on the patient's main limitation.

In patients using respiratory equipment:

- for patients with COPD treated with oxygen long-term or to deal with an acute event, the supply of oxygen during exercise, particularly in subjects displaying hypoxaemia, will allow a higher exercise intensity to be reached, through several mechanisms [191]. In addition, by correcting the hypoxaemia, the risk of inducing functional ischaemia is reduced. As part of limiting this risk, it is recommended that oxygen saturation be maintained above 90% throughout the duration of exercise training. For any patient treated with oxygen, it is recommended that the pulmonologist be contacted to prescribe the appropriate system, educate the patient on the use of the material and ensure long-term follow-up. In France, cardiologists can only prescribe short-term oxygen therapy – lasting 1 month and renewable twice. If the dependence on oxygen therapy limits the capacity for rehabilitation, the patient should be referred to pulmonary rehabilitation;
- for patients with COPD treated with non-invasive ventilation long-term or to deal with an acute event, the pulmonologist should be contacted. In France, cardiologists cannot prescribe

initial treatment with non-invasive ventilation upon discharge from hospital. If the reliance on non-invasive ventilation limits the capacity for rehabilitation, the patient should be referred to pulmonary rehabilitation;

- some patients with COPD require long-term treatment with continuous positive airway pressure (CPAP) for central sleep apnoea or obstructive sleep apnoea syndrome (OSAS). A patient treated with CPAP must continue their treatment during the cardiovascular rehabilitation. In partnership with the patient's service providers, rehabilitation is a good time to verify that the patient is complying with their treatment, and that there is no residual apnoea/hypopnoea. If compliance and/or tolerance are sub-optimal, or if the treatment is insufficiently effective, the doctor monitoring the patient for their apnoea should be contacted.

#### 10.5.2. OSAS

Screening is recommended during cardiovascular rehabilitation as:

- OSAS is much more frequent in cardiac patients than in the general population [192] and OSAS is a cardiovascular risk factor;
- screening for OSAS should particularly target patients with evocative symptoms, obesity, resistant hypertension, aortic dissection, severe HF, nocturnal arrhythmia or for whom the index event occurred during the night. It is also justified for professional drivers;
- the usual questionnaires (STOP-Bang, Berlin questionnaire, Epworth scale) are less sensitive in cardiovascular patients than in the general population. Other screening methods can be used (saturation, nasal flow rate, connected devices, etc.). Diagnosis will be based on polygraphy or polysomnography readings, preferably performed at the end of the patient's hospital stay due to the overestimation of OSAS during the acute care phase.

If OSAS is diagnosed, the treatments offered have beneficial effects on clinical symptoms, arrhythmia, hypertension, any pulmonary arterial hypertension, B-type natriuretic peptide levels, and sometimes, left ventricular ejection fraction. It is recommended that these treatments be implemented during cardiac rehabilitation. They include dietary hygiene measures (weight loss, physical activity, smoking cessation, reducing alcohol intake, discontinuation of some medications and sleeping position), exercise training and ventilation by CPAP. The SERVE-HF study [193] showed an unfavourable effect of servo-assisted ventilation on total mortality and mortality among patients with systolic HF and central sleep apnoea. Indications for mandibular advancement devices, palate or tongue surgery or stimulation of the hypoglossal nerve and diaphragm stimulation require a specialist opinion.

#### 10.5.3. Chronic kidney disease

Chronic kidney disease is associated with very high cardiovascular morbidity-mortality [194]. From the first stages of chronic kidney disease, a specific multifactorial myopathy is observed, and its severity increases with disease stage. The consequences of this myopathy are sarcopenia and reduced exercise capacity, frequently associated with frailty syndrome, reduced QoL, high sedentarity and an increased risk of death [195]. For these patients, cardiac rehabilitation programmes are associated with improved exercise capacity and cardiovascular prognosis [196,197], they have been demonstrated to be safe and not to exacerbate renal dysfunction [198]. The principles of cardiac rehabilitation are similar to those for patients without renal disease:

- a CPET is recommended; the risk of musculoskeletal complications requires increased vigilance at advanced stages of CRD [199];
- optimization of the cardiovascular treatment must be associated with reassessment of blood potassium levels and renal function after any treatment adjustment, or in case of dehydration;
- specificities for patients treated by dialysis [200]: the presence of an arteriovenous fistula is not a contraindication for exercise once the fistula has healed. The arteriovenous fistula must be protected from potential trauma and not be compressed. The rehabilitation sessions should be programmed before or the day after a dialysis session;
- specificities for patients treated by peritoneal dialysis [201]: exercise can be undertaken when the peritoneal space is full or empty, depending on their personal preference. Swimming (or balneotherapy) is not contraindicated for peritoneal dialysis patients, on condition that there is no skin damage at the catheter outlet and that the dressing is changed after the session;
- with regard to dietary regime: before dialysis, it is generally low-sodium (6 g salt/day), low-potassium, low-protein (0.8–1.0 g/kg/day), but taking care not to be too strict to avoid causing undernutrition, particularly in older people and/or those with frailty syndrome. When treated by dialysis, protein intake must be increased to 1.3–1.4 g/kg/day and calorie intake to 35–40 kcal/kg/day.

## 11. Organizational aspects

Cardiac rehabilitation may be proposed in residential or ambulatory settings, preferably ambulatory.

### 11.1. Legislation

The two decrees from 11 January 2022 relate to the general conditions of implementation and to the technical conditions of rehabilitation services (called 'Soins Médicaux et de Réadaptation') and provide additional information on the specific conditions required for cardiac rehabilitation [202,203]. These decrees are completed by ministerial instructions relative to the authorization to carry out Medical Care and Rehabilitation Services (DGOS instructions 28 September 2023). These decrees have been in force since 1 June 2023, institutions have a year to comply with the stipulations after notification of their accreditation by the regional health authority.

The medical care and rehabilitation activity provided in rehabilitation institutions aim to prevent or reduce the consequences of cardiovascular diseases, before or in the aftermath of acute care episodes. This activity includes diagnostic and therapeutic interventions and actions related to prevention, therapeutic education and occupational reinsertion in the context of the patient's personal therapeutic project.

The main points in the reform include the following:

- 'aftercare and rehabilitation' institutions become 'medical care and rehabilitation institutions', with their own medical activity to account for the progression of severity observed in the patient profiles;
- institutions must propose in- and outpatient rehabilitation as required by the patient's profile. Telehealth services and mobile teams are specifically mentioned;
- specialized medical consultations can be proposed within the rehabilitation institution or in direct relation with the institution, upon request from other rehabilitation institutions;
- institutions can act in the framework of a Multiannual Goals and Means Contract (Contrat Pluriannuel d'Objectif et de Moyens)

- for expertise under the heading 'patient management in early rehabilitation after acute cardiological events';
- it is now obligatory that a psychologist be integrated into the team.

The regulatory aspects of the organization of care in cardiology-specialized rehabilitation institutions include:

- complex, multidisciplinary and intensive rehabilitation lasting at least 3 hours per day should be started as soon as compatible with the patient's functional capacity. The duration is systematically adapted to the patient's state of health;
- implementation of at least two of the following therapies: physiotherapy, occupational therapy, dietetics, psychological support, therapeutic education and adapted physical activity;
- in the context of complete hospitalization or at each hospital consultation, at least two individual or group treatment sequences must be provided.

### 11.2. In practice: GERS-P recommendations

The main objectives for cardiac rehabilitation are as follows: improve prognosis by reducing morbidity-mortality, improve exercise capacity to sustain effort and QoL for the patient, secondary prevention by correcting cardiovascular risk factors, optimizing pharmacological treatment, socio-professional reinsertion and developing the patient's self-care skills through therapeutic education.

#### 11.2.1. Staff

**11.2.1.1. Medical competencies.** Due to the potential complexity of the cardiovascular diseases dealt with, the risk of life-threatening events and the specific skills required, the Société française de cardiologie (French Society of Cardiology) recommends that a doctor, who is a recognized specialist in cardiology and vascular diseases or in cardiovascular diseases, takes on the medical responsibility and coordination of rehabilitation institutions specializing in cardiovascular disorders. A minimum of two doctors, including the coordinator, are required.

It is recommended that the coordinating cardiologist have recognized competencies (university diploma/degree) in the field of cardiac rehabilitation. In addition to monitoring and adapting therapies, the cardiologist approves patient admissions and, in collaboration with the multidisciplinary team and the patient, establishes a therapeutic project that is periodically re-assessed.

Depending on needs, the medical team should include other specialists such as the general practitioner, endocrinologist or nutritionist, psychiatrist, tobacco expert, occupational physician, pulmonologist, etc.

**11.2.1.2. Multidisciplinary team.** In addition to the professionals indicated in the legal general conditions (one nurse and one social worker), the multidisciplinary team must include:

- at least one physiotherapist;
- at least one dietician;
- at least one psychologist.

The paramedical team can also include other skill sets: adapted physical activity coach (coaching, supervised group exercises), nurse's aide, occupational therapist, etc. It is essential that all personnel be regularly trained in emergency procedures and in therapeutic education activities.

### 11.2.2. The facilities

**11.2.2.1. Residential and day-care cardiac rehabilitation.** The building must be adapted to the different modalities of care provided and make it possible for the patient's friends and family to accompany them.

The residential rehabilitation must include rooms with one or two beds, equipped with a call system.

For day-care hospitalization, a rest area is required.

In all cases, the rooms available must be designed to allow an emergency response in a timeline compatible with the safety requirements.

**11.2.2.2. Rehabilitation areas and equipment must include.** An 'emergency room' fitted out to allow emergency procedures and cardiac resuscitation to be performed before patient transfer (one or more beds with an emergency trolley, heart monitors, defibrillator, intubation, and ventilation material, piped gas supply, etc.).

Emergency trolleys must be available in sufficient numbers and geographically placed to cope with any emergency occurring in the unit. An emergency trolley must be present in the exercise test room during tests, and near training rooms. Devices to monitor blood pressure and an ECG must also be available along with:

- first-responder treatments with medication and material for injection and infusion;
- an approved cardioverter defibrillator;
- intubation and ventilation material;
- medical fluids and material for aspiration;
- the use-before dates and working order of the material must be checked regularly.

A technical platform where non-invasive examinations can be performed to assess patient functional evaluation and for monitoring purposes. The obligatory medico-technical equipment includes a standard ECG, a telemetric monitoring system, equipment for exercise tests, an echocardiograph and a vascular Doppler ultrasound. The minimal desirable elements are: a device to analyse ventilatory expired gas during exercise, a Holter ECG recording device, a pulse oximeter, an ambulatory blood pressure monitoring device and heart rate monitors.

Access to a computed tomography scanner and magnetic resonance imaging, and the possibility to request medical biology analyses are also required.

An exercise training platform: the material available must allow the whole reconditioning and education programme to be implemented: gym equipment (weights, barres, benches, mats, etc.), various training machines (cycle ergometer, treadmill, rowing machine, segmentary weight bench, arm ergometer, etc.), monitoring equipment (ECG, heart rate, blood pressure, glycaemia, etc.). All training rooms must be equipped with an emergency call system (telephone or other). Each patient must have at least 4 m<sup>2</sup> of personal space in the gym room. A therapeutic pool and access to outdoor circuits can be added, depending on the possibilities for each centre.

A space for physiotherapy for individual consultations.

A room dedicated to relaxation is desirable.

A room is required to provide information and therapeutic education to patients and their families, educational audiovisual equipment and teaching tools should be available.

### 11.2.3. Continuity and permanence of care, emergency management

Continuity of care (i.e. during the day, on working days) is ensured by a nurse present on site throughout the period when patients are present. A cardiologist must be able to intervene immediately if necessary. Permanence of care (nights and week-

ends, bank holidays) is ensured by an on-duty or on-call specialist in cardiovascular medicine, or a doctor with experience in life-threatening emergency interventions and at least one nurse. Emergency medical intervention must be possible at any time.

The possibility to transfer patients at any time and within a reasonable timeframe to an intensive care unit must be organized based on a formalized agreement. All emergency protocols must be set out in writing, validated and distributed. The emergency call procedures must be known to all personnel and tested regularly. In the context of part-time hospitalization, the patient is informed of what to do if abnormal clinical symptoms occur.

### 11.3. Quality criteria

Despite the scientific documentation available, rehabilitation programmes remain heterogeneous. Beyond the criteria relating to infrastructure and equipment, human resources and organization that are dealt with in specific chapters, criteria to monitor the quality of the programmes could be proposed with a view to standardization of care [204–206].

Among the criteria retained by the ESC, the GERS-P proposes the following self-assessment criteria: % patients effectively admitted out of those referred, waiting time, % sessions completed out of those planned, % lost to follow-up or discontinuing cardiac rehabilitation, % patients evaluated before and after the programme, % treatment optimization, improvement of exercise capacity and muscle strength, reduction of anxiety/depression scores, % verification of cardiovascular risk factors. In addition, internal and/or external audits, participation in scientific activities and in educational training (for health care professionals), development of innovations, collaborations with the various sectors and with other rehabilitation centres should be encouraged.

### 11.4. Barriers to cardiac rehabilitation

Despite extensive scientific proof of the benefits of cardiac rehabilitation, the number of patients availing of it remains low. The factors negatively influencing participation may be classed as follows [207].

#### 11.4.1. Inherent to the patient

In addition to advanced age or generally altered state and limiting comorbidities, more than 20% of patients refuse rehabilitation when offered, sometimes due to a need to return rapidly to work, or to a lack of motivation, and ignorance of the programmes and benefits.

Women, even young women, are also less frequently included than men according to several studies.

#### 11.4.2. Inherent to the rehabilitation structures

Insufficient in number, waiting time for admission considered too long, poorly distributed geographically, their usefulness is not well covered in medical training, and they are often not very financially attractive.

#### 11.4.3. Inherent to the medical corps

The duration of management of acute events has been reduced and the technical revascularization act takes precedence over the need for long-term management. Reticence persists among the medical corps (who do not see the point). However, patients who have undergone bypass surgery more often access rehabilitation centres after surgery compared to patients treated by angioplasty.

### 11.5. Alternatives to cardiac rehabilitation in centres

The small number of patients benefiting from cardiovascular rehabilitation in dedicated centres requires alternatives to be found. The barriers to participation are varied (distance from home, socio-professional constraints, long wait for admission, etc.). Several modalities are currently being tested: development of light structures where personalized programmes can be proposed (content, times, etc.), particularly adapted to the active working segment of the population.

The development of home-based rehabilitation (tele-rehabilitation) has been dealt with in publications, and a comparable efficacy to conventional cardiac rehabilitation has been reported in various populations and for various diseases after assessment and piloting by a cardiac rehabilitation centre. Consequently, the modality is included in recommendations [208–210]. There are numerous advantages for patients (rapid enrolment, integration in the family context, reduced commute time, etc.), but the disadvantages must not be overlooked (lower motivation, loneliness, anxiety, etc.). These require specific organization (tele-monitoring with all the necessary precautions, precise initial assessment of the patient's medical state and psychosocial context) to ensure rehabilitation achieves similar levels to those attained in a centre (accounting for risk factors, therapeutic education, exercise training, compliance with treatment, etc.).

## 12. Medico-economic aspects of cardiac rehabilitation

Despite the wide diversity of programmes, most studies show that cardiac rehabilitation has a favourable cost-benefit ratio compared to no rehabilitation [211]. Economic analyses [212] suggest that the hospitalizations avoided absorb all the direct costs of a cardiac rehabilitation programme. Various studies show that, after smoking cessation, exercise training is the best prevention strategy. Currently ongoing French studies of home-based rehabilitation and tele-rehabilitation open up the possibility of catering for a larger eligible population, leading to better health care coverage in France, and potentially reduced costs.

## 13. Conclusions, perspectives

Broader indications, more targeted training methods, more varied multidisciplinary teams, the existence of expert centres, and an increasing level of proof for various diseases make rehabilitation an indispensable mode of treatment, to which patients should have easier access in order to improve their prognosis.

A patient assessment is performed by the cardiologist before the start of the rehabilitation programme in order to avoid risks and tailor the programme to the patient's needs, capacities and expectations. Although the proportion of patients with HF benefiting from rehabilitation has increased and must continue to do so, there are still too many – including heart disease patients, patients with congenital cardiopathies, older subjects and women – who do not have access. The indications must be communicated to all those involved in the patient's trajectory to ensure that the patient can be referred to cardiac rehabilitation after diagnosis or at any time during the progression of their chronic disease.

The prescription of training with details on frequency, intensity, duration and type of activity allows greater precision and harmonization of practices, with the objective of leading the patient to make progress and to engage long-term with regular physical activity in phase III. Structured therapeutic education programmes make the patient more autonomous, allowing them to live safely with their disease. Finally, therapeutic optimization, which is facilitated during rehabilitation, often makes it possible to attain recom-

mended treatment objectives. Cardiac rehabilitation is also the ideal context to introduce psychosocial monitoring and to take comorbidities into account, thus improving the patient's lived experience, reducing the consequences of their disease and increasing their chances of returning to professional activity.

The decrees from 2022 set out the modalities for functioning, the skill-sets necessary, as well as the safety and quality criteria applied to rehabilitation institutions.

Finally, the future of cardiac rehabilitation, to benefit the largest possible number of patients, will require the implementation of alternative forms that are simpler, more flexible, more tailored, and provided in centres, at a distance or at home. The objective is to be able to offer each patient the form that suits them, depending on the severity of their disease, their needs, motivation and geographical situation, as well as their personal, familial and professional availability. These adaptations should help to disseminate this safe and effective patient management technique – that is both appreciated by patients and is completely relevant in terms of public health – as widely as possible.

## Disclosure of interest

The authors declare that they have no competing interest.

## References

- [1] Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2021;42:3227–337, <http://dx.doi.org/10.1093/eurheartj/ehab484>.
- [2] Dibben GO, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. *Eur Heart J* 2023;44:452–69, <http://dx.doi.org/10.1093/eurheartj/ehac747>.
- [3] McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;42:3599–726, <http://dx.doi.org/10.1093/eurheartj/ehab368>.
- [4] Pavy B, Iliou MC, Verges-Patois B, Brion R, Monpere C, Carre F, et al. French Society of Cardiology guidelines for cardiac rehabilitation in adults. *Arch Cardiovasc Dis* 2012;105:309–28, <http://dx.doi.org/10.1016/j.acvd.2012.01.010>.
- [5] Ambrosetti M, Abreu A, Corrà U, Davos CH, Hansen D, Frederix I, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: from knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. *Eur J Prev Cardiol* 2021;28:460–95, <http://dx.doi.org/10.1177/2047487320913379>.
- [6] Pavy B, Iliou MC, Guy JM, Tabet JY, Ponchon-Weess A, Pierre B, et al. MEDICAL TReatment Optimization in cardiac rehabilitation (METRO study): a French multicenter study. *Ann Cardiol Angeiol (Paris)* 2021;70:275–80, <http://dx.doi.org/10.1016/j.ancard.2021.08.009>.
- [7] Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2018;39:119–77, <http://dx.doi.org/10.1093/eurheartj/ehx393>.
- [8] Puymirat E, Bonaca M, Iliou MC, Tea V, Ducrocq G, Douard H, et al. Outcome associated with prescription of cardiac rehabilitation according to predicted risk after acute myocardial infarction: insights from the FAST-MI registries. *Arch Cardiovasc Dis* 2019;112:459–68, <http://dx.doi.org/10.1016/j.acvd.2019.04.002>.
- [9] Ekblom Ö, Cider A, Hambraeus K, Back M, Leosdottir M, Lonn A, et al. Participation in exercise-based cardiac rehabilitation is related to reduced total mortality in both men and women: results from the SWEDEHEART registry. *Eur J Prev Cardiol* 2022;29:485–92, <http://dx.doi.org/10.1093/eurjpc/zwab083>.
- [10] Salzwedel A, Jensen K, Rauch B, Doherty P, Metzendorf MI, Hackbusch M, et al. Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease patients treated according to contemporary evidence based medicine: update of the Cardiac Rehabilitation Outcome Study (CROS-II). *Eur J Prev Cardiol* 2020;27:1756–74, <http://dx.doi.org/10.1177/2047487320905719>.
- [11] Iliou MC, Pavy B, Martinez J, Corone S, Meurin P, Tuppin P, et al. Exercise training is safe after coronary stenting: a prospective multicentre study. *Eur J Prev Cardiol* 2015;22:27–34, <http://dx.doi.org/10.1177/2047487313505819>.
- [12] Haykowsky M, Scott J, Esch B, Schopflocher D, Myers J, Paterson I, et al. A meta-analysis of the effects of exercise training on left ventricular remodeling following myocardial infarction: start early and go longer for greatest exercise benefits on remodeling. *Trials* 2011;12:92, <http://dx.doi.org/10.1186/1745-6215-12-92>.



[13] Pattyn N, Vanhees L, Cornelissen VA, Coeckelberghs E, De Maeyer C, Goetschalckx K, et al. The long-term effects of a randomized trial comparing aerobic interval versus continuous training in coronary artery disease patients: 1-year data from the SAINTEX-CAD study. *Eur J Prev Cardiol* 2016;23:1154–64, <http://dx.doi.org/10.1177/2047487316631200>.

[14] Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J* 2020;41:407–77, <http://dx.doi.org/10.1093/eurheartj/ehz425>.

[15] Buckley BJR, de Koning IA, Harrison SL, Fazio-Eynullayeva E, Underhill P, Kemps HMC, et al. Exercise-based cardiac rehabilitation vs. percutaneous coronary intervention for chronic coronary syndrome: impact on morbidity and mortality. *Eur J Prev Cardiol* 2022;29:1074–80, <http://dx.doi.org/10.1093/eurjpc/zwab191>.

[16] Yang X, Li Y, Ren X, Xiong X, Wu L, Li J, et al. Effects of exercise-based cardiac rehabilitation in patients after percutaneous coronary intervention: a meta-analysis of randomized controlled trials. *Sci Rep* 2017;7:44789, <http://dx.doi.org/10.1038/srep44789>.

[17] Adlam D, Alfonso F, Maas A, Vrints C, Writing C. European Society of Cardiology, acute cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection. *Eur Heart J* 2018;39:3353–68, <http://dx.doi.org/10.1093/eurheartj/ehy080>.

[18] Meurin P, Tabet JY, Thabut G, Cristofini P, Farrokhi T, Fischbach M, et al. Nonsteroidal anti-inflammatory drug treatment for postoperative pericardial effusion: a multicenter randomized, double-blind trial. *Ann Intern Med* 2010;152:137–43, <http://dx.doi.org/10.7326/0003-4819-152-3-201002020-00004>.

[19] Origuchi H, Itoh H, Momomura SI, Nohara R, Daida H, Masuda T, et al. Active participation in outpatient cardiac rehabilitation is associated with better prognosis after coronary artery bypass graft surgery – J-REHAB CABG Study. *Circ J* 2020;84:427–35, <http://dx.doi.org/10.1253/circj.CJ-19-0650>.

[20] Griffo R, Ambrosetti M, Tramarin R, Fattiroli F, Temporelli PL, Vestri AR, et al. Effective secondary prevention through cardiac rehabilitation after coronary revascularization and predictors of poor adherence to lifestyle modification and medication. Results of the ICAROS Survey. *Int J Cardiol* 2013;167:1390–5, <http://dx.doi.org/10.1016/j.ijcard.2012.04.069>.

[21] Goel K, Pack QR, Lahr B, Greason KL, Lopez-Jimenez F, Squires RW, et al. Cardiac rehabilitation is associated with reduced long-term mortality in patients undergoing combined heart valve and CABG surgery. *Eur J Prev Cardiol* 2015;22:159–68, <http://dx.doi.org/10.1177/2047487313512219>.

[22] Savage PD, Rengo JL, Menzies KE, Ades PA. Cardiac rehabilitation after heart valve surgery: comparison with coronary artery bypass graft patients. *J Cardiopulm Rehabil Prev* 2015;35:231–7, <http://dx.doi.org/10.1097/HCR.000000000000104>.

[23] Hansen TB, Berg SK, Sibillitz KL, Søgaard R, Thygesen LC, Yazbeck AM, et al. Availability of, referral to and participation in exercise-based cardiac rehabilitation after heart valve surgery: results from the national CopenHeart survey. *Eur J Prev Cardiol* 2015;22:710–8, <http://dx.doi.org/10.1177/2047487314536364>.

[24] Sibillitz KL, Berg SK, Tang LH, Risom SS, Glud C, Lindschou J, et al. Exercise-based cardiac rehabilitation for adults after heart valve surgery. *Cochrane Database Syst Rev* 2016;3:CD010876, <http://dx.doi.org/10.1002/14651858.CD010876.pub2>.

[25] Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2022;43:561–632, <http://dx.doi.org/10.1093/eurheartj/ehab395>.

[26] Fuglsang S, Heiberg J, Hjortdal VE, Laustsen S. Exercise-based cardiac rehabilitation in surgically treated type-A aortic dissection patients. *Scand Cardiovasc J* 2017;51:99–105, <http://dx.doi.org/10.1080/14017431.2016.1257149>.

[27] Zhou N, Fortin G, Balice M, Kovalska O, Cristofini P, Ledru F, et al. Evolution of early postoperative cardiac rehabilitation in patients with acute type A aortic dissection. *J Clin Med* 2022;11, <http://dx.doi.org/10.3390/jcm11082107>.

[28] Schwaab B, Rauch B, Völler H, Benzer W, Schmid JP. Beyond randomised studies: recommendations for cardiac rehabilitation following repair of thoracic aortic aneurysm or dissection. *Eur J Prev Cardiol* 2022;28:e17–9, <http://dx.doi.org/10.1177/2047487320936782>.

[29] Steinmetz C, Bjarnason-Wehrens B, Baumgarten H, Walther T, Mengden T, Walther C. Prehabilitation in patients awaiting elective coronary artery bypass graft surgery – effects on functional capacity and quality of life: a randomized controlled trial. *Clin Rehabil* 2020;34:1256–67, <http://dx.doi.org/10.1177/0269215520933950>.

[30] Myers J, Niebauer J, Humphrey R. Prehabilitation coming of age: implications for cardiac and pulmonary rehabilitation. *J Cardiopulm Rehabil Prev* 2021;41:141–6, <http://dx.doi.org/10.1097/HCR.0000000000000574>.

[31] Kleczynski P, Trebacz J, Stapor M, Sobczynski R, Konstany-Kalandyck J, Kapelak B, et al. Inpatient cardiac rehabilitation after transcatheter aortic valve replacement is associated with improved clinical performance and quality of life. *J Clin Med* 2021;10, <http://dx.doi.org/10.3390/jcm10102125>.

[32] Eichler S, Völler H, Reibis R, Wegscheider K, Butter C, Harnath A, et al. Geriatric or cardiac rehabilitation? Predictors of treatment pathways in advanced age patients after transcatheter aortic valve implantation. *BMC Cardiovasc Disord* 2020;20:158, <http://dx.doi.org/10.1186/s12872-020-01452-x>.

[33] Schlott A, Lubos E, Guha M, Hegeler-Molkewehrum C, Sudau M, Schmidt H. [Aftercare of patients after MitraClip® implantation]. *Herz* 2017;42:176–85, <http://dx.doi.org/10.1007/s00059-016-4448-y>.

[34] Nakaya Y, Akamatsu M, Ogimoto A, Kitaoka H. Early cardiac rehabilitation for acute decompensated heart failure safely improves physical function (PEARL study): a randomized controlled trial. *Eur J Phys Rehabil Med* 2021;57:985–93, <http://dx.doi.org/10.23736/S1973-9087.21.06727-7>.

[35] Acanfora D, Scicchitano P, Casucci G, Lanzillo B, Capuano N, Furgi G, et al. Exercise training effects on elderly and middle-age patients with chronic heart failure after acute decompensation: a randomized, controlled trial. *Int J Cardiol* 2016;225:313–23, <http://dx.doi.org/10.1016/j.ijcard.2016.10.026>.

[36] Bozkurt B, Fonarow GC, Goldberg LR, Guglin M, Josephson RA, Forman DE, et al. Cardiac rehabilitation for patients with heart failure: JACC Expert Panel. *J Am Coll Cardiol* 2021;77:1454–69, <http://dx.doi.org/10.1016/j.jacc.2021.01.030>.

[37] Taylor JL, Holland DJ, Keating SE, Leveritt MD, Gomersall SR, Rowlands AV, et al. Short-term and long-term feasibility, safety, and efficacy of high-intensity interval training in cardiac rehabilitation: the FITR Heart Study Randomized Clinical Trial. *JAMA Cardiol* 2020;5:1382–9, <http://dx.doi.org/10.1001/jamacardio.2020.3511>.

[38] Fidalgo ASF, Farinatti P, Borges JP, de Paula T, Monteiro W. Institutional guidelines for resistance exercise training in cardiovascular disease: a systematic review. *Sports Med* 2019;49:463–75, <http://dx.doi.org/10.1007/s40279-019-01059-z>.

[39] Fisher S, Smart NA, Pearson MJ. Resistance training in heart failure patients: a systematic review and meta-analysis. *Heart Fail Rev* 2022;27:1665–82, <http://dx.doi.org/10.1007/s10741-021-10169-8>.

[40] Fernandez-Rubio H, Becerro-de-Bengoa-Vallejo R, Rodriguez-Sanz D, Calvo-Lobo C, Vicente-Campos D, Chicharro JL. Inspiratory muscle training in patients with heart failure. *J Clin Med* 2020;9:29–36, <http://dx.doi.org/10.3390/jcm9061710>.

[41] Laoutaris ID, Piotrowicz E, Kallistratos MS, Dritsas A, Dimaki N, Miliopoulos D, et al. Combined aerobic/resistance/inspiratory muscle training as the ‘optimum’ exercise programme for patients with chronic heart failure: ARISTOS-HF randomized clinical trial. *Eur J Prev Cardiol* 2021;28:1626–35, <http://dx.doi.org/10.1093/eurjpc/zwaa091>.

[42] Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, Coats AJ, et al. Exercise-based cardiac rehabilitation for adults with heart failure. *Cochrane Database Syst Rev* 2019;1:CD003331, <http://dx.doi.org/10.1002/14651858.CD003331.pub5>.

[43] Taylor RS, Walker S, Ciani O, Warren F, Smart NA, Piepoli M, et al. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRA-MATCH II individual participant data meta-analysis. *Health Technol Assess* 2019;23:1–98, <http://dx.doi.org/10.3310/hta23250>.

[44] Bjarnason-Wehrens B, Nebel R, Jensen K, Hackbusch M, Grilli M, Gielen S, et al. Exercise-based cardiac rehabilitation in patients with reduced left ventricular ejection fraction: the Cardiac Rehabilitation Outcome Study in Heart Failure (CROS-HF): a systematic review and meta-analysis. *Eur J Prev Cardiol* 2020;27:929–52, <http://dx.doi.org/10.1177/2047487319854140>.

[45] Sabbag A, Mazin I, Rott D, Hay I, Gang N, Tzur B, et al. The prognostic significance of improvement in exercise capacity in heart failure patients who participate in cardiac rehabilitation programme. *Eur J Prev Cardiol* 2018;25:354–61, <http://dx.doi.org/10.1177/2047487317750427>.

[46] Tabet JY, Meurin P, Benzidi Y, Beauvais F, Ben Driss A, Weber H, et al. Greater prognostic value of peak VO<sub>2</sub> after exercise training program completion in heart failure patients. *Int J Cardiol* 2013;168:4139–44, <http://dx.doi.org/10.1016/j.ijcard.2013.07.076>.

[47] Swank AM, Horton J, Fleg JL, Fonarow GC, Ketyeyan S, Goldberg L, et al. Modest increase in peak VO<sub>2</sub> is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training. *Circ Heart Fail* 2012;5:579–85, <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.111.965186>.

[48] Mentz RJ, Whellan DJ, Reeves GR, Pastva AM, Duncan P, Upadhyya B, et al. Rehabilitation intervention in older patients with acute heart failure with preserved versus reduced ejection fraction. *JACC Heart Fail* 2021;9:747–57, <http://dx.doi.org/10.1016/j.jchf.2021.05.007>.

[49] Kitzman DW, Whellan DJ, Duncan P, Pastva AM, Mentz RJ, Reeves GR, et al. Physical rehabilitation for older patients hospitalized for heart failure. *N Engl J Med* 2021;385:203–16, <http://dx.doi.org/10.1056/NEJMoa2026141>.

[50] Mueller S, Winzer EB, Duvinage A, Gevaert AB, Edelmann F, Haller B, et al. Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial. *JAMA* 2021;325:542–51, <http://dx.doi.org/10.1001/jama.2020.26812>.

[51] Popovic D, Arena R, Guazzi M. A flattening oxygen consumption trajectory phenotypes disease severity and poor prognosis in patients with heart failure with reduced, mid-range, and preserved ejection fraction. *Eur J Heart Fail* 2018;20:1115–24, <http://dx.doi.org/10.1002/ehf.1140>.

[52] Grosman-Rimon L, Hui S, Santos S, Vadasz B, Foroutan F, Farrell A, et al. Exercise rehabilitation in cardiac resynchronization: systematic review and meta-analysis. *Heart Fail Rev* 2021;26:507–19, <http://dx.doi.org/10.1007/s10741-020-10049-7>.

[53] Cattadori G, Baravelli M, Di Marco S, Picozzi A. Cardiac resynchronization therapy and training in heart failure: a perfect marriage? *Int J Cardiol* 2020;299:177–9, <http://dx.doi.org/10.1016/j.ijcard.2019.10.005>.

[54] Santa-Clara H, Abreu A, Melo X, Santos V, Cunha P, Oliveira M, et al. High-intensity interval training in cardiac resynchronization therapy: a randomized control trial. *Eur J Appl Physiol* 2019;119:1757–67, <http://dx.doi.org/10.1007/s00421-019-04165-y>.

- [55] Mahfood Haddad T, Saurav A, Smer A, Azzouz MS, Akinapelli A, Williams MA, et al. Cardiac rehabilitation in patients with left ventricular assist device: a systematic review and meta-analysis. *J Cardiopulm Rehabil Prev* 2017;37:390–6, <http://dx.doi.org/10.1097/HCR.0000000000000254>.
- [56] Adamopoulos S, Corrà U, Laoutaris ID, Pistono M, Agostoni PG, Coats AJS, et al. Exercise training in patients with ventricular assist devices: a review of the evidence and practical advice. A position paper from the Committee on Exercise Physiology and Training and the Committee of Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2019;21:3–13, <http://dx.doi.org/10.1002/ehf.1352>.
- [57] Reiss N, Schmidt T, Langheim E, Bjarnason-Wehrens B, Marx R, Sindermann JR, et al. Inpatient cardiac rehabilitation of LVAD patients—updated recommendations from the Working Group of the German Society for Prevention and Rehabilitation of Cardiovascular Diseases. *Thorac Cardiovasc Surg* 2021;69:70–82, <http://dx.doi.org/10.1055/s-0039-1691837>.
- [58] Scaglione A, Panzarino C, Modica M, Tavanelli M, Pezzano A, Grati P, et al. Short- and long-term effects of a cardiac rehabilitation program in patients implanted with a left ventricular assist device. *PLoS One* 2021;16:e0259927, <http://dx.doi.org/10.1371/journal.pone.0259927>.
- [59] Squires RW, Bonikowski AR. Cardiac rehabilitation for heart transplant patients: considerations for exercise training. *Prog Cardiovasc Dis* 2022;70:40–8, <http://dx.doi.org/10.1016/j.pcad.2021.12.003>.
- [60] Ciolac EG, Castro RE, Marçal IR, Bacal F, Bocchi EA, Guimarães GV. Cardiac reinnervation affects cardiorespiratory adaptations to exercise training in individuals with heart transplantation. *Eur J Prev Cardiol* 2020;27:1151–61, <http://dx.doi.org/10.1177/2047487319880650>.
- [61] Costa R, Moreira E, Silva Cardoso J, Azevedo LF, Ribeiro JA, Pinto R. Effectiveness of exercise-based cardiac rehabilitation for heart transplant recipients: a systematic review and meta-analysis. *Health Serv Insights* 2023;16, <http://dx.doi.org/10.1177/11786329231161482> [11786329231161482].
- [62] Kourek C, Karatzanos E, Nanas S, Karabinis A, Dimopoulos S. Exercise training in heart transplantation. *World J Transplant* 2021;11:466–79, <http://dx.doi.org/10.5500/wjt.v11.i11.466>.
- [63] Taylor RS, Dalal HM, McDonagh STJ. The role of cardiac rehabilitation in improving cardiovascular outcomes. *Nat Rev Cardiol* 2022;19:180–94, <http://dx.doi.org/10.1038/s41569-021-00611-7>.
- [64] Uithoven KE, Smith JR, Medina-Inojosa JR, Squires RW, Van Iterson EH, Olson TP. Clinical and rehabilitative predictors of peak oxygen uptake following cardiac transplantation. *J Clin Med* 2019;8:119–29, <http://dx.doi.org/10.3390/jcm8010119>.
- [65] Hageman D, Fokkenrood HJ, Gommans LN, van den Houten MM, Teijink JA. Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. *Cochrane Database Syst Rev* 2018;4:CD005263, <http://dx.doi.org/10.1002/14651858.CD005263.pub4>.
- [66] van den Houten MML, Hageman D, Gommans LNM, Kleijnen J, Scheltinga MRM, Teijink JAW. The effect of supervised exercise, home based exercise and endovascular revascularisation on physical activity in patients with intermittent claudication: a network meta-analysis. *Eur J Vasc Endovasc Surg* 2019;58:383–92, <http://dx.doi.org/10.1016/j.ejvs.2018.12.023>.
- [67] Mazzolai L, Belch J, Venermo M, Aboyans V, Brodmann M, Bura-Riviere A, et al. Exercise therapy for chronic symptomatic peripheral artery disease. *Eur Heart J* 2024;45:1303–21, <http://dx.doi.org/10.1093/eurheartj/ehad734>.
- [68] Harwood AE, Pymer S, Ingle L, Doherty P, Chetter IC, Parmenter B, et al. Exercise training for intermittent claudication: a narrative review and summary of guidelines for practitioners. *BMJ Open Sport Exerc Med* 2020;6:e000897, <http://dx.doi.org/10.1136/bmjsem-2020-000897>.
- [69] McDermott MM, Dayanidhi S, Kosmac K, Saini S, Slysz J, Leeuwenburgh C, et al. Walking exercise therapy effects on lower extremity skeletal muscle in peripheral artery disease. *Circ Res* 2021;128:1851–67, <http://dx.doi.org/10.1161/CIRCRESAHA.121.318242>.
- [70] McDermott MM, Spring B, Tian L, Treat-Jacobson D, Ferrucci L, Lloyd-Jones D, et al. Effect of low-intensity vs. high-intensity home-based walking exercise on walk distance in patients with peripheral artery disease: the LITE randomized clinical trial. *JAMA* 2021;325:1266–76, <http://dx.doi.org/10.1001/jama.2021.2536>.
- [71] Jansen SC, Abaraogu UO, Lauret GJ, Fakhry F, Fokkenrood HJ, Teijink JA. Modes of exercise training for intermittent claudication. *Cochrane Database Syst Rev* 2020;8:CD009638, <http://dx.doi.org/10.1002/14651858.CD009638.pub3>.
- [72] Bearne LM, Volkmer B, Peacock J, Sekhon M, Fisher G, Galea Holmes MN, et al. Effect of a home-based, walking exercise behavior change intervention vs. usual care on walking in adults with peripheral artery disease: the MOSAIC Randomized Clinical Trial. *JAMA* 2022;327:1344–55, <http://dx.doi.org/10.1001/jama.2022.3391>.
- [73] Cambou JP, Aboyans V, Constans J, Lacroix P, Dentans C, Bura A. Characteristics and outcome of patients hospitalised for lower extremity peripheral artery disease in France: the COPART Registry. *Eur J Vasc Endovasc Surg* 2010;39:577–85, <http://dx.doi.org/10.1016/j.ejvs.2010.02.009>.
- [74] Pedretti RFE, Iliou MC, Israel CW, Abreu A, Miljoen H, Corra U, et al. Comprehensive multicomponent cardiac rehabilitation in cardiac implantable electronic devices recipients: a consensus document from the European Association of Preventive Cardiology (EAPC); Secondary prevention and rehabilitation section) and European Heart Rhythm Association (EHRA). *Eur J Prev Cardiol* 2021;28:1736–52, <http://dx.doi.org/10.1093/eurjpc/zwaa121>.
- [75] Versteeg H, Timmermans I, Meine M, Zitron E, Mabo P, Denollet J. Prevalence and risk markers of early psychological distress after ICD implantation in the European REMOTE-CIED study cohort. *Int J Cardiol* 2017;240:208–13, <http://dx.doi.org/10.1016/j.ijcard.2017.03.124>.
- [76] Piccini JP, Hellkamp AS, Whellan DJ, Ellis SJ, Keteyian SJ, Kraus WE, et al. Exercise training and implantable cardioverter-defibrillator shocks in patients with heart failure: results from HF-ACTION (Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training). *JACC Heart Fail* 2013;1:142–8, <http://dx.doi.org/10.1016/j.jchf.2013.01.005>.
- [77] Cosgun MS, Cosgun C. Efficacy and safety of different exercises in preventing cardiac implantable electronic device-related shoulder impairment. *Pacing Clin Electrophysiol* 2022;45:384–92, <http://dx.doi.org/10.1111/pace.14465>.
- [78] Pandey A, Parashar A, Moore C, Ngo C, Salahuddin U, Bhargava M, et al. Safety and efficacy of exercise training in patients with an implantable cardioverter-defibrillator: a meta-analysis. *JACC Clin Electrophysiol* 2017;3:117–26, <http://dx.doi.org/10.1016/j.jacep.2016.06.008>.
- [79] Kovacs AH, Kaufman TM, Broberg CS. Cardiac rehabilitation for adults with congenital heart disease: physical and psychosocial considerations. *Can J Cardiol* 2018;34:S270–7, <http://dx.doi.org/10.1016/j.cjca.2018.07.016>.
- [80] Meyer M, Brudy L, Garcia-Cuenillas L, Hager A, Ewert P, Oberhoffer R, et al. Current state of home-based exercise interventions in patients with congenital heart disease: a systematic review. *Heart* 2020;106:333–41, <http://dx.doi.org/10.1136/heartjnl-2019-315680>.
- [81] Kempny A, Dimopoulos K, Uebing A, Moceri P, Swan L, Gatzoulis MA, et al. Reference values for exercise limitations among adults with congenital heart disease. Relation to activities of daily life – single centre experience and review of published data. *Eur Heart J* 2012;33:1386–96, <http://dx.doi.org/10.1093/eurheartj/ehr461>.
- [82] Budts W, Pielecs GE, Roos-Hesselink JW, Sanz de la Garza M, D’Ascenzi F, Gianakoulas G, et al. Recommendations for participation in competitive sport in adolescent and adult athletes with Congenital Heart Disease (CHD): position statement of the Sports Cardiology & Exercise Section of the European Association of Preventive Cardiology (EAPC), the European Society of Cardiology (ESC) Working Group on Adult Congenital Heart Disease and the Sports Cardiology, Physical Activity and Prevention Working Group of the Association for European Paediatric and Congenital Cardiology (AEPC). *Eur Heart J* 2020;41:4191–9, <http://dx.doi.org/10.1093/eurheartj/ehaa501>.
- [83] Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. *Eur Heart J* 2021;42:563–645, <http://dx.doi.org/10.1093/eurheartj/ehaa554>.
- [84] Williams CA, Wadey C, Pielecs G, Stuart G, Taylor RS, Long L. Physical activity interventions for people with congenital heart disease. *Cochrane Database Syst Rev* 2020;10:CD013400, <http://dx.doi.org/10.1002/14651858.CD013400.pub2>.
- [85] Meree D, Ehlken N, Kreuzer S, Ghofrani S, Hoepfer MM, Halank M, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. *Circulation* 2006;114:1482–9, <http://dx.doi.org/10.1161/CIRCULATIONAHA.106.618397>.
- [86] Galè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J* 2016;37:67–119, <http://dx.doi.org/10.1093/eurheartj/ehv317>.
- [87] Grünig E, Benjamin N, Kruger U, Kaemmerer H, Harutyunova S, Olsson KM, et al. General measures and supportive therapy for pulmonary arterial hypertension: updated recommendations from the Cologne Consensus Conference 2018. *Int J Cardiol* 2018;272S:30–6, <http://dx.doi.org/10.1016/j.ijcard.2018.08.085>.
- [88] Pelliccia A, Solberg EE, Papadakis M, Adami PE, Biffi A, Caselli S, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). *Eur Heart J* 2019;40:19–33, <http://dx.doi.org/10.1093/eurheartj/ehy730>.
- [89] Dias KA, Link MS, Levine BD. Exercise training for patients with hypertrophic cardiomyopathy: JACC review topic of the week. *J Am Coll Cardiol* 2018;72:1157–65, <http://dx.doi.org/10.1016/j.jacc.2018.06.054>.
- [90] Steinberg BA, Li Z, O’Brien EC, Pritchard J, Chew DS, Bunch TJ, et al. Atrial fibrillation burden and heart failure: data from 39,710 individuals with cardiac implanted electronic devices. *Heart Rhythm* 2021;18:709–16, <http://dx.doi.org/10.1016/j.hrthm.2021.01.021>.
- [91] Risom SS, Zwisler AD, Johansen PP, Sibillitz KL, Lindschou J, Glud C, et al. Exercise-based cardiac rehabilitation for adults with atrial fibrillation. *Cochrane Database Syst Rev* 2017;2:CD011197, <http://dx.doi.org/10.1002/14651858.CD011197.pub2>.
- [92] Bryde RE, Cooper Jr LT, Fairweather D, Di Florio DN, Martinec MW. Exercise after acute myocarditis: when and how to return to sports. *Cardiol Clin* 2023;41:107–15, <http://dx.doi.org/10.1016/j.ccl.2022.08.009>.
- [93] Marcadet DM, Pavy B, Bosser G, Claudot F, Corone S, Douard H, et al. French Society of Cardiology guidelines on exercise tests (part 1): methods and interpretation. *Arch Cardiovasc Dis* 2018;111:782–90, <http://dx.doi.org/10.1016/j.acvd.2018.05.005>.



[94] Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). *Eur Heart J* 2020;41:543–603, <http://dx.doi.org/10.1093/eurheartj/ehz405>.

[95] Iliou MC, Monpere C. Chapter 6: early assessment and risk stratification. In: Abreu A, Schmid JP, Piepoli M, editors. *ESC handbook of cardiovascular rehabilitation: a practical clinical guide*. Oxford: ESC publications; 2020. p. 41–8.

[96] Hansen D, Abreu A, Ambrosetti M, Cornelissen V, Gevaert A, Kemps H, et al. Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: why and how: a position statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. *Eur J Prev Cardiol* 2022;29:230–45, <http://dx.doi.org/10.1093/eurjpc/zwab007>.

[97] Ramos Haddad Garcia MI, Ricci-Vitor AL, Vanzella LM, Franca da Silva AK, Takahashi C, Ribeiro F, et al. Interrater reliability across 7 established risk stratification protocols in cardiac rehabilitation. *Arch Phys Med Rehabil* 2021;102:470–9, <http://dx.doi.org/10.1016/j.apmr.2020.08.020>.

[98] Gevaert AB, Adams V, Bahls M, Bowen TS, Cornelissen V, Dorr M, et al. Towards a personalised approach in exercise-based cardiovascular rehabilitation: how can translational research help? A 'call to action' from the Section on Secondary Prevention and Cardiac Rehabilitation of the European Association of Preventive Cardiology. *Eur J Prev Cardiol* 2020;27:1369–85, <http://dx.doi.org/10.1177/2047487319877716>.

[99] Sabbahi A, Canada JM, Babu AS, Severin R, Arena R, Ozemek C. Exercise training in cardiac rehabilitation: setting the right intensity for optimal benefit. *Prog Cardiovasc Dis* 2022;70:58–65, <http://dx.doi.org/10.1016/j.pcad.2022.02.001>.

[100] Nichols S, McGregor G, Breckon J, Ingle L. Current insights into exercise-based cardiac rehabilitation in patients with coronary heart disease and chronic heart failure. *Int J Sports Med* 2021;42:19–26, <http://dx.doi.org/10.1055/a-1198-5573>.

[101] Patti A, Merlo L, Ambrosetti M, Sarto P. Exercise-based cardiac rehabilitation programs in heart failure patients. *Heart Fail Clin* 2021;17:263–71, <http://dx.doi.org/10.1016/j.hfc.2021.01.007>.

[102] Iliou MC, Verges-Patois B, Pavy B, Charles-Nelson A, Monpere C, Richard R, et al. Effects of combined exercise training and electromyostimulation treatments in chronic heart failure: a prospective multicentre study. *Eur J Prev Cardiol* 2017;24:1274–82, <http://dx.doi.org/10.1177/2047487317712601>.

[103] Robertson RJ, Goss FL, Rutkowski J, Lenz B, Dixon C, Timmer J, et al. Concurrent validation of the OMNI perceived exertion scale for resistance exercise. *Med Sci Sports Exerc* 2003;35:333–41, <http://dx.doi.org/10.1249/01.MSS.0000048831.15016.2A>.

[104] Légifrance. Arrêté du 30 décembre 2020 relatif au cahier des charges des programmes d'éducation thérapeutique du patient et à la composition du dossier de déclaration et modifiant l'arrêté du 2 août 2010 modifié relatif aux compétences requises pour dispenser ou coordonner l'éducation thérapeutique du patient, <https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000042845767> [accessed 27 May 2024].

[105] Haute Autorité de santé. Éducation thérapeutique du patient. Définition, finalités et organisation; 2007 [accessed 27 May 2024] <https://www.has-sante.fr/upload/docs/application/pdf/etp.-definition.-finalites.-recommandations.juin.2007.pdf>.

[106] Pavy B, Barbet R, Carre F, Champion C, Iliou MC, Jourdain P, et al. Therapeutic education in coronary heart disease: position paper from the Working Group of Exercise Rehabilitation and Sport (GERS) and the Therapeutic Education Commission of the French Society of Cardiology. *Arch Cardiovasc Dis* 2013;106:680–9, <http://dx.doi.org/10.1016/j.acvd.2013.10.002>.

[107] de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation* 1999;99:779–85, <http://dx.doi.org/10.1161/01.cir.99.6.779>.

[108] Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. *N Engl J Med* 2018;378:e34, <http://dx.doi.org/10.1056/NEJMoa1800389>.

[109] Delgado-Lista J, Alcalá-Díaz JF, Torres-Pena JD, Quintana-Navarro GM, Fuentes F, García-Ríos A, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. *Lancet* 2022;399:1876–85, [http://dx.doi.org/10.1016/S0140-6736\(22\)00122-2](http://dx.doi.org/10.1016/S0140-6736(22)00122-2).

[110] Ministère des Solidarités et de la Santé. Programme national nutrition santé 2019–2023. <https://sante.gouv.fr/IMG/pdf/pnns4.2019-2023.pdf> [accessed 27 May 2024].

[111] Paillard F, Flageol O, Mahe G, Laviolle B, Dourmap C, Auffret V. Validation and reproducibility of a short food frequency questionnaire for cardiovascular prevention. *Arch Cardiovasc Dis* 2021;114:570–6, <http://dx.doi.org/10.1016/j.acvd.2020.12.008>.

[112] Benowitz NL, Liakoni E. Tobacco use disorder and cardiovascular health. *Addiction* 2022;117:1128–38, <http://dx.doi.org/10.1111/add.15703>.

[113] Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. *JAMA* 2003;290:86–97, <http://dx.doi.org/10.1001/jama.290.1.86>.

[114] Rigotti NA, McDermott MM. Smoking cessation and cardiovascular disease: it's never too early or too late for action. *J Am Coll Cardiol* 2019;74:508–11, <http://dx.doi.org/10.1016/j.jacc.2019.06.003>.

[115] Rigotti NA, Kruse GR, Livingstone-Banks J, Hartmann-Boyce J. Treatment of tobacco smoking: a review. *JAMA* 2022;327:566–77, <http://dx.doi.org/10.1001/jama.2022.0395>.

[116] Pack QR, Priya A, Lagu TC, Pekow PS, Atreya A, Rigotti NA, et al. Short-term safety of nicotine replacement in smokers hospitalized with coronary heart disease. *J Am Heart Assoc* 2018;7:e009424, <http://dx.doi.org/10.1161/JAHA.118.009424>.

[117] Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. *Cochrane Database Syst Rev* 2019;4:CD013308, <http://dx.doi.org/10.1002/14651858.CD013308>.

[118] Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. *BMJ* 2014;348:g1151, <http://dx.doi.org/10.1136/bmj.g1151>.

[119] Pipe AL, Mir H. E-cigarettes reexamined: product toxicity. *Can J Cardiol* 2022;38:1395–405, <http://dx.doi.org/10.1016/j.cjca.2022.08.001>.

[120] Odani S, Tsuno K, Agaku IT, Tabuchi T. Heated tobacco products do not help smokers quit or prevent relapse: a longitudinal study in Japan. *Tob Control* 2023;472–80, <http://dx.doi.org/10.1136/tpc-2022-057613>.

[121] Dillinger JG, Pezel T, Fauvel C, Delmas C, Schurtz G, Trimaille A, et al. Prevalence of psychoactive drug use in patients hospitalized for acute cardiac events: rationale and design of the ADDICT-ICCU trial, from the Emergency and Acute Cardiovascular Care Working Group and the National College of Cardiologists in Training of the French Society of Cardiology. *Arch Cardiovasc Dis* 2022;115:514–20, <http://dx.doi.org/10.1016/j.acvd.2022.05.012>.

[122] Ghannem M, Belhadj I, Tritar A, Moukala T, Amri N, Noury A, et al. [Cannabis and acute coronary syndrome with ST segment elevation]. *Ann Cardiol Angeiol (Paris)* 2013;62:424–8, <http://dx.doi.org/10.1016/j.ancard.2013.09.002>.

[123] Légifrance. Arrêté du 28 juillet 2017 portant inscription dispositif d'automatisme de l'INR COAGUCHEK INRANGE de la société ROCHE DIAGNOSTICS au titre I<sup>er</sup> de la liste des produits et prestations remboursables prévue à l'article L. 165-1 du Code de la sécurité sociale. <https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000035329082> [accessed 27 May 2024].

[124] Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023 ESC Guidelines for the management of endocarditis. *Eur Heart J* 2023;44:3948–4042, <http://dx.doi.org/10.1093/eurheartj/ehad193>.

[125] Légifrance. Arrêté du 28 mars 2022 fixant la liste des affections médicales incompatibles ou compatibles avec ou sans aménagements ou restrictions pour l'obtention, le renouvellement ou le maintien du permis de conduire ou pouvant donner lieu à la délivrance de permis de conduire de durée de validité limitée (refonte). <https://www.legifrance.gouv.fr/eli/arrete/2022/3/28/INTS2206503A/JO/texte> [accessed 27 May 2024].

[126] Hammadah M, Kindya BR, Allard-Ratick MP, Jazbeh S, Eapen D, Wilson Tang WH, et al. Navigating air travel and cardiovascular concerns: is the sky the limit? *Clin Cardiol* 2017;40:660–6, <http://dx.doi.org/10.1002/clc.22741>.

[127] Mallet RT, Burtscher J, Richalet JP, Millet GP, Burtscher M. Impact of high altitude on cardiovascular health: current perspectives. *Vasc Health Risk Manag* 2021;17:317–35, <http://dx.doi.org/10.2147/VHRM.S294121>.

[128] Steinke EE, Jaarsma T, Barnason SA, Byrne M, Doherty S, Dougherty CM, et al. Sexual counselling for individuals with cardiovascular disease and their partners: a consensus document from the American Heart Association and the ESC Council on Cardiovascular Nursing and Allied Professions (CCNAP). *Eur Heart J* 2013;34:3217–35, <http://dx.doi.org/10.1093/eurheartj/ehz270>.

[129] Bosser G, Chodek-Hingray A, Kazmierczak C, Juilliere Y. [Sexual activity and cardiovascular risks]. *Presse Med* 2014;43:1097–105, <http://dx.doi.org/10.1016/j.jpm.2014.06.005>.

[130] Hackett G, Kirby M, Wylie K, Heald A, Ossei-Gerning N, Edwards D, et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction in men – 2017. *J Sex Med* 2018;15:430–57, <http://dx.doi.org/10.1016/j.jsxm.2018.01.023>.

[131] Rothenbacher D, Dallmeier D, Mons U, Rosamond W, Koenig W, Brenner H. Sexual activity patterns before myocardial infarction and risk of subsequent cardiovascular adverse events. *J Am Coll Cardiol* 2015;66:1516–7, <http://dx.doi.org/10.1016/j.jacc.2015.07.053>.

[132] Levine GN, Steinke EE, Bakaeen FG, Bozkurt B, Cheitlin MD, Conti JB, et al. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation* 2012;125:1058–72, <http://dx.doi.org/10.1161/CIR.0b013e3182447787>.

[133] Thakker R, Khan M, Al-Hemyari B. Cardiac rehabilitation after hospitalization for acute coronary syndrome. *Curr Cardiol Rep* 2023;25:1699–703, <http://dx.doi.org/10.1007/s11886-023-02010-5>.

[134] Goyal P, Gorodeski EZ, Marcum ZA, Forman DE. Cardiac rehabilitation to optimize medication regimens in heart failure. *Clin Geriatr Med* 2019;35:549–60.

[135] Visco V, Ferruzzi GJ, Nicastro F, Virtuoso N, Carrizzo A, Galasso G, et al. Artificial intelligence as a business partner in cardiovascular precision medicine: an emerging approach for disease detection and treatment optimization. *Curr Med Chem* 2021;28:6569–90, <http://dx.doi.org/10.2174/0929867328666201218122633>.

[136] Levine GN. The mind-heart-body connection. *Circulation* 2019;140:1363–5, <http://dx.doi.org/10.1161/CIRCULATIONAHA.119.041914>.

[137] Dhar AK, Barton DA. Depression and the link with cardiovascular disease. *Front Psychiatry* 2016;7:33, <http://dx.doi.org/10.3389/fpsy.2016.00033>.

[138] Kupper N, Denollet J. Type D personality as a risk factor in coronary heart disease: a review of current evidence. *Curr Cardiol Rep* 2018;20:104, <http://dx.doi.org/10.1007/s11886-018-1048-x>.

[139] Pogossova N, Saner H, Pedersen SS, Cupples ME, McGee H, Hofer S, et al. Psychosocial aspects in cardiac rehabilitation: From theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. *Eur J Prev Cardiol* 2015;22:1290–306, <http://dx.doi.org/10.1177/2047487314543075>.

[140] Mesa-Vieira C, Grolimund J, von Kanel R, Franco OH, Saner H. Psychosocial risk factors in cardiac rehabilitation: time to screen beyond anxiety and depression. *Glob Heart* 2021;16:16, <http://dx.doi.org/10.5334/gh.896>.

[141] Hamad R, Penko J, Kazi DS, Coxson P, Guzman D, Wei PC, et al. Association of low socioeconomic status with premature coronary heart disease in US adults. *JAMA Cardiol* 2020;5:899–908, <http://dx.doi.org/10.1001/jamacardio.2020.1458>.

[142] Deschênes SS, Kivimaki M, Schmitz N. Adverse childhood experiences and the risk of coronary heart disease in adulthood: examining potential psychological, biological, and behavioral mediators in the Whitehall II Cohort Study. *J Am Heart Assoc* 2021;10:e019013, <http://dx.doi.org/10.1161/JAHA.120.019013>.

[143] Boersma SN, Maes S, van Elderen T. Goal disturbance predicts health-related quality of life and depression 4 months after myocardial infarction. *Br J Health Psychol* 2005;10:615–30, <http://dx.doi.org/10.1348/135910705X52525>.

[144] Kure CE, Chan YK, Ski CF, Thompson DR, Carrington MJ, Stewart S. Gender-specific secondary prevention? Differential psychosocial risk factors for major cardiovascular events. *Open Heart* 2016;3:e000356, <http://dx.doi.org/10.1136/openhrt-2015-000356>.

[145] van Montfort E, Denollet J, Widdershoven J, Kupper N. Validity of the European Society of Cardiology's psychosocial screening interview in patients with coronary artery disease – The THORESCI Study. *Psychosom Med* 2017;79:404–15, <http://dx.doi.org/10.1097/PSY.0000000000000433>.

[146] Levine GN, Lange RA, Bairey-Merz CN, Davidson RJ, Jamerson K, Mehta PK, et al. Meditation and cardiovascular risk reduction: a scientific statement from the American Heart Association. *J Am Heart Assoc* 2017;6:e002218, <http://dx.doi.org/10.1161/JAHA.117.002218>.

[147] Nijjar PS, Connett JE, Lindquist R, Brown R, Burt M, Pergolski A, et al. Randomized trial of mindfulness-based stress reduction in cardiac patients eligible for cardiac rehabilitation. *Sci Rep* 2019;9:18415, <http://dx.doi.org/10.1038/s41598-019-54932-2>.

[148] Sweda R, Siontis GCM, Nikolakopoulou A, Windecker S, Pilgrim T. Antidepressant treatment in patients following acute coronary syndromes: a systematic review and Bayesian meta-analysis. *ESC Heart Fail* 2020;7:3610–20, <http://dx.doi.org/10.1002/ehf2.12861>.

[149] von Kanel R, Schmid JP, Meister-Langraf RE, Barth J, Znoj H, Schnyder U, et al. Pharmacotherapy in the management of anxiety and pain during acute coronary syndromes and the risk of developing symptoms of posttraumatic stress disorder. *J Am Heart Assoc* 2021;10:e018762, <http://dx.doi.org/10.1161/JAHA.120.018762>.

[150] Pierre B. Cœur et travail. <https://www.fnac.com/a6521881/Bernard-Pierre-Coeur-et-travail> [accessed 27 May 2024].

[151] Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett Jr DR, Tudor-Locke C, et al. 2011 Compendium of Physical Activities: a second update of codes and MET values. *Med Sci Sports Exerc* 2011;43:1575–81, <http://dx.doi.org/10.1249/MSS.0b013e31821ece12>.

[152] Reibis R, Salzwedel A, Abreu A, Corra U, Davos C, Doehner W, et al. The importance of return to work: how to achieve optimal reintegration in ACS patients. *Eur J Prev Cardiol* 2019;26:1358–69, <http://dx.doi.org/10.1177/2047487319839263>.

[153] Karasek R, Theorell T. *Healthy work: stress, productivity, and the reconstruction of the working life*. New York: Basic Books; 1990.

[154] Rantanen J, Feldt T, Hyvonen K, Kinnunen U, Makikangas A. Factorial validity of the effort-reward imbalance scale: evidence from multi-sample and three-wave follow-up studies. *Int Arch Occup Environ Health* 2013;86:645–56, <http://dx.doi.org/10.1007/s00420-012-0798-9>.

[155] Sara JD, Prasad M, Eleid MF, Zhang M, Widmer RJ, Lerman A. Association between work-related stress and coronary heart disease: a review of prospective studies through the job strain, effort-reward balance, and organizational justice models. *J Am Heart Assoc* 2018;7:e008073, <http://dx.doi.org/10.1161/JAHA.117.008073>.

[156] Banzer JA, Maguire TE, Kennedy CM, O'Malley CJ, Balady GJ. Results of cardiac rehabilitation in patients with diabetes mellitus. *Am J Cardiol* 2004;93:81–4, <http://dx.doi.org/10.1016/j.amjcard.2003.09.017>.

[157] Mourrot L, Boussuges A, Maunier S, Chopra S, Riviere F, Debussche X, et al. Cardiovascular rehabilitation in patients with diabetes. *J Cardiopulm Rehabil Prev* 2010;30:157–64, <http://dx.doi.org/10.1097/HCR.0b013e3181c565fe>.

[158] Beacco M, Verges-Patois B, Blonde MC, Crevisy E, Hachbi M, Bouillet B, et al. Characteristics of diabetic patients and diabetes care in cardiac rehabilitation. *Arch Cardiovasc Dis* 2014;107:391–7, <http://dx.doi.org/10.1016/j.acvd.2014.05.004>.

[159] Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J* 2020;41:255–323, <http://dx.doi.org/10.1093/eurheartj/ehz486>.

[160] Inserm. 8 – Obésité et diabète de type 2. [https://www.ipubli.inserm.fr/bitstream/handle/10608/9690/Chapitre\\_8.html](https://www.ipubli.inserm.fr/bitstream/handle/10608/9690/Chapitre_8.html) [accessed 27 May 2024].

[161] Inserm. Activité physique : prévention et traitement des maladies chroniques. <https://www.inserm.fr/expertise-collective/activite-physique-prevention-et-traitement-maladies-chroniques/> [accessed 27 May 2024].

[162] Vergès B, Patois-Vergès B, Iliou MC, Simoneau-Robin I, Bertrand JH, Feige JM, et al. Influence of glycemic control on gain in VO<sub>2</sub> peak, in patients with type 2 diabetes enrolled in cardiac rehabilitation after an acute coronary syndrome. The prospective DARE study. *BMC Cardiovasc Disord* 2015;15:64, <http://dx.doi.org/10.1186/s12872-015-0055-8>.

[163] Duclos M, Oppert JM, Vergès B, Coliche V, Gautier JF, Guezennec Y, et al. Physical activity and type 2 diabetes. Recommendations of the SFD (Francophone Diabetes Society) diabetes and physical activity working group. *Diabetes Metab* 2013;39:205–16, <http://dx.doi.org/10.1016/j.diabet.2013.03.005>.

[164] Kemps H, Kränkel N, Dörr M, Moholdt T, Wilhelm M, Paneni F, et al. Exercise training for patients with type 2 diabetes and cardiovascular disease: what to pursue and how to do it. A Position Paper of the European Association of Preventive Cardiology (EAPC). *Eur J Prev Cardiol* 2019;26:709–27, <http://dx.doi.org/10.1177/2047487318820420>.

[165] Umpierre D, Ribeiro PA, Kramer CK, Leitao CB, Zucatti AT, Azevedo MJ, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. *JAMA* 2011;305:1790–9, <http://dx.doi.org/10.1001/jama.2011.576>.

[166] Vergès B, Avignon A, Bonnet F, Catargi B, Cattani S, Cosson E, et al. Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome. *Arch Cardiovasc Dis* 2012;105:239–53, <http://dx.doi.org/10.1016/j.acvd.2012.01.008>.

[167] Milani RV, Lavie CJ. Behavioral differences and effects of cardiac rehabilitation in diabetic patients following cardiac events. *Am J Med* 1996;100:517–23, [http://dx.doi.org/10.1016/s0002-9343\(96\)00020-4](http://dx.doi.org/10.1016/s0002-9343(96)00020-4).

[168] Vergès B, Patois-Vergès B, Goueslard K, Cottenet J, Nguyen A, Tatulashvili S, et al. High efficacy of screening for diabetes and prediabetes in cardiac rehabilitation after an acute coronary syndrome (ACS). The REHABDIAB study. *Diabetes Metab* 2019;45:79–82, <http://dx.doi.org/10.1016/j.diabet.2017.05.012>.

[169] Tatulashvili S, Patois-Vergès B, Nguyen A, Blonde MC, Vergès B. Detection of glucose metabolism disorders in coronary patients enrolled in cardiac rehabilitation: is glycated haemoglobin useful? Data from the prospective REHABDIAB study. *Eur J Prev Cardiol* 2018;25:464–71, <http://dx.doi.org/10.1177/2047487317754011>.

[170] Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. *Circulation* 2019;139:e997–1012, <http://dx.doi.org/10.1161/CIR.0000000000000679>.

[171] Venturini E, Iannuzzo G, D'Andrea A, Pacileo M, Tarantini L, Canale ML, et al. Oncology and cardiac rehabilitation: an underrated relationship. *J Clin Med* 2020;9:1810, <http://dx.doi.org/10.3390/jcm9061810>.

[172] Shultz AM, Squires RW, Shin JY, Durani U, Pophali PA. Cardio-oncology rehabilitation (CORE) exercise prescription and programming: a practical guide. *J Cardiopulm Rehabil Prev* 2021;41:341–4, <http://dx.doi.org/10.1097/HCR.0000000000000572>.

[173] Grave C, Gabet A, Iliou MC, Cinaud A, Tuppin P, Blacher J, et al. Temporal trends in admission for cardiac rehabilitation after an acute coronary syndrome in France from 2009 to 2021: persistent sex, age and social disparities. *Arch Cardiovasc Dis* 2024;117:234–43, <http://dx.doi.org/10.1016/j.acvd.2023.12.008>.

[174] Suaya JA, Stason WB, Ades PA, Normand SL, Shepard DS. Cardiac rehabilitation and survival in older coronary patients. *J Am Coll Cardiol* 2009;54:25–33, <http://dx.doi.org/10.1016/j.jacc.2009.01.078>.

[175] Vigorito C, Abreu A, Ambrosetti M, Belardinelli R, Corra U, Cupples M, et al. Frailty and cardiac rehabilitation: a call to action from the EAPC Cardiac Rehabilitation Section. *Eur J Prev Cardiol* 2017;24:577–90, <http://dx.doi.org/10.1177/2047487316682579>.

[176] Kumar KR, Pina IL. Cardiac rehabilitation in older adults: new options. *Clin Cardiol* 2020;43:163–70, <http://dx.doi.org/10.1002/clc.23296>.

[177] Fiuza-Luces C, Santos-Lozano A, Joyner M, Carrera-Bastos P, Picazo O, Zugaza JL, et al. Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors. *Nat Rev Cardiol* 2018;15:731–43, <http://dx.doi.org/10.1038/s41569-018-0065-1>.

[178] Cadore EL, Pinto RS, Bottaro M, Izquierdo M. Strength and endurance training prescription in healthy and frail elderly. *Aging Dis* 2014;5:183–95, <http://dx.doi.org/10.14336/AD.2014.0500183>.

[179] Dun Y, Smith JR, Liu S, Olson TP. High-intensity interval training in cardiac rehabilitation. *Clin Geriatr Med* 2019;35:469–87, <http://dx.doi.org/10.1016/j.cger.2019.07.011>.

[180] Grave C, Gabet A, Cinaud A, Tuppin P, Blacher J, Olie V. Nationwide time trends in patients hospitalized for acute coronary syndrome: a worrying generational and social effect among women. *Eur J Prev Cardiol* 2024;31:116–27, <http://dx.doi.org/10.1093/eurjpc/zwad288>.

[181] García M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular disease in women: clinical perspectives. *Circ Res* 2016;118:1273–93, <http://dx.doi.org/10.1161/CIRCRESAHA.116.307547>.

[182] Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. *BMJ* 2006;332:73–8, <http://dx.doi.org/10.1136/bmj.38678.389583.7C>.

[183] Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. *Lancet* 2011;378:1297–305, [http://dx.doi.org/10.1016/S0140-6736\(11\)60781-2](http://dx.doi.org/10.1016/S0140-6736(11)60781-2).



[184] Gee MA, Viera AJ, Miller PF, Tolleson-Rinehart S. Functional capacity in men and women following cardiac rehabilitation. *J Cardiopulm Rehabil Prev* 2014;34:255–62, <http://dx.doi.org/10.1097/HCR.0000000000000066>.

[185] Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta-analysis. *J Am Coll Cardiol* 2016;67:1–12, <http://dx.doi.org/10.1016/j.jacc.2015.10.044>.

[186] Haute Autorité de santé. Sexe, genre et santé – Rapport d'analyse prospective 2020. [https://www.has-sante.fr/jcms/p\\_3223570/fr/sexe-genre-et-sante-rapport-d-analyse-prospective-2020](https://www.has-sante.fr/jcms/p_3223570/fr/sexe-genre-et-sante-rapport-d-analyse-prospective-2020) [accessed 27 May 2024].

[187] Global Initiative for Chronic Obstructive Lung Disease. 2022 Global Strategy for prevention, diagnosis and management of COPD. <https://goldcopd.org/2022-gold-reports/> [accessed 27 May 2024].

[188] McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2015;2015:CD003793, <http://dx.doi.org/10.1002/14651858.CD003793.pub3>.

[189] Haute Autorité de santé. BPCCO : des indicateurs de qualité pour évaluer le parcours de soins des patients. [https://www.has-sante.fr/jcms/p\\_3329428/fr/bpcco-des-indicateurs-de-qualite-pour-evaluer-le-parcours-de-soins-des-patients](https://www.has-sante.fr/jcms/p_3329428/fr/bpcco-des-indicateurs-de-qualite-pour-evaluer-le-parcours-de-soins-des-patients) [accessed 27 May 2024].

[190] Garvey C, Bayles MP, Hamm LF, Hill K, Holland A, Limberg TM, et al. Pulmonary rehabilitation exercise prescription in chronic obstructive pulmonary disease: review of selected guidelines: an official statement from the American Association of Cardiovascular and Pulmonary Rehabilitation. *J Cardiopulm Rehabil Prev* 2016;36:75–83, <http://dx.doi.org/10.1097/HCR.0000000000000171>.

[191] Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. *Am J Respir Crit Care Med* 2013;188:e13–64, <http://dx.doi.org/10.1164/rccm.201309-1634ST>.

[192] Fox H, Purucker HC, Holzhaecker I, Tebtmann U, Bitter T, Horstkotte D, et al. Prevalence of sleep-disordered breathing and patient characteristics in a coronary artery disease cohort undergoing cardiovascular rehabilitation. *J Cardiopulm Rehabil Prev* 2016;36:421–9, <http://dx.doi.org/10.1097/HCR.0000000000000192>.

[193] Cowie MR, Woehrle H, Wegscheider K, Angermann C, d'Ortho MP, Erdmann E, et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. *N Engl J Med* 2015;373:1095–105, <http://dx.doi.org/10.1056/NEJMoa1506459>.

[194] Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004;351:1296–305, <http://dx.doi.org/10.1056/NEJMoa041031>.

[195] Roshanravan B, Gamboa J, Wilund K. Exercise and CKD: skeletal muscle dysfunction and practical application of exercise to prevent and treat physical impairments in CKD. *Am J Kidney Dis* 2017;69:837–52, <http://dx.doi.org/10.1053/j.ajkd.2017.01.051>.

[196] Venkataraman R, Sanderson B, Bittner V. Outcomes in patients with chronic kidney disease undergoing cardiac rehabilitation. *Am Heart J* 2005;150:1140–6, <http://dx.doi.org/10.1016/j.ahj.2005.01.048>.

[197] Völler H, Gitt A, Jannowitz C, Karoff M, Karmann B, Pittrow D, et al. Treatment patterns, risk factor control and functional capacity in patients with cardiovascular and chronic kidney disease in the cardiac rehabilitation setting. *Eur J Prev Cardiol* 2014;21:1125–33, <http://dx.doi.org/10.1177/2047487313482285>.

[198] Thompson S, Wiebe N, Arena R, Rouleau C, Aggarwal S, Wilton SB, et al. Effectiveness and utilization of cardiac rehabilitation among people with CKD. *Kidney Int Rep* 2021;6:1537–47, <http://dx.doi.org/10.1016/j.ekir.2021.03.889>.

[199] Johansen KL, Painter P. Exercise in individuals with CKD. *Am J Kidney Dis* 2012;59:126–34, <http://dx.doi.org/10.1053/j.ajkd.2011.10.008>.

[200] Wilund KR, Jeong JH, Greenwood SA. Addressing myths about exercise in hemodialysis patients. *Semin Dial* 2019;32:297–302, <http://dx.doi.org/10.1111/sdi.12815>.

[201] Bennett PN, Bohm C, Harasemiw O, Brown L, Gabrys I, Jegatheesan D, et al. Physical activity and exercise in peritoneal dialysis: International Society for Peritoneal Dialysis and the Global Renal Exercise Network practice recommendations. *Perit Dial Int* 2022;42:8–24, <http://dx.doi.org/10.1177/08968608211055290>.

[202] Légifrance. Décret n° 2022-24 du 11 janvier 2022 relatif aux conditions d'implantation de l'activité de soins médicaux et de réadaptation. <https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000044947210> [accessed 27 May 2024].

[203] Légifrance. Décret n° 2022-25 du 11 janvier 2022 relatif aux conditions techniques de fonctionnement de l'activité de soins médicaux et de réadaptation. <https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000044947234> [accessed 27 May 2024].

[204] Abreu A, Frederix I, Dendale P, Janssen A, Doherty P, Piepoli MF, et al. Standardization and quality improvement of secondary prevention through cardiovascular rehabilitation programmes in Europe: the avenue towards EAPC accreditation programme: a position statement of the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology (EAPC). *Eur J Prev Cardiol* 2021;28:496–509, <http://dx.doi.org/10.1177/2047487320924912>.

[205] Cowie A, Buckley J, Doherty P, Furze G, Hayward J, Hinton S, et al. Standards and core components for cardiovascular disease prevention and rehabilitation. *Heart* 2019;105:510–5, <http://dx.doi.org/10.1136/heartjnl-2018-314206>.

[206] Wilhelm M, Abreu A, Adami PE, Ambrosetti M, Antonopoulou M, Biffi A, et al. EAPC core curriculum for preventive cardiology. *Eur J Prev Cardiol* 2022;29:251–74, <http://dx.doi.org/10.1093/eurjpc/zwab017>.

[207] Khadanga S, Gaalema DE, Savage P, Ades PA. Underutilization of cardiac rehabilitation in women: barriers and solutions. *J Cardiopulm Rehabil Prev* 2021;41:207–13, <http://dx.doi.org/10.1097/HCR.0000000000000629>.

[208] Brouwers RWM, van Exel HJ, van Hal JMC, Jorstad HT, de Kluiver EP, Kraaijenhagen RA, et al. Cardiac telerehabilitation as an alternative to centre-based cardiac rehabilitation. *Neth Heart J* 2020;28:443–51, <http://dx.doi.org/10.1007/s12471-020-01432-y>.

[209] Thomas RJ, Beatty AL, Beckie TM, Brewer LC, Brown TM, Forman DE, et al. Home-based cardiac rehabilitation: a scientific statement from the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology. *J Am Coll Cardiol* 2019;74:133–53, <http://dx.doi.org/10.1016/j.jacc.2019.03.008>.

[210] Frederix I, Caiani EG, Dendale P, Anker S, Bax J, Bohm A, et al. ESC e-Cardiology Working Group Position Paper: overcoming challenges in digital health implementation in cardiovascular medicine. *Eur J Prev Cardiol* 2019;26:1166–77, <http://dx.doi.org/10.1177/2047487319832394>.

[211] Edwards K, Jones N, Newton J, Foster C, Judge A, Jackson K, et al. The cost-effectiveness of exercise-based cardiac rehabilitation: a systematic review of the characteristics and methodological quality of published literature. *Health Econ Rev* 2017;7:37, <http://dx.doi.org/10.1186/s13561-017-0173-3>.

[212] Shields GE, Wells A, Doherty P, Heagerty A, Buck D, Davies LM. Cost-effectiveness of cardiac rehabilitation: a systematic review. *Heart* 2018;104:1403–10, <http://dx.doi.org/10.1136/heartjnl-2017-312809>.